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ABSTRACT  
 
COMBINATORIAL LIBRARIES OF STILBENE FUSED CHALCONE 
AND FLAVANONE DERIVATIVES: 
 SYNTHESIS AND ANTI-PROLIFERATIVE PROPERTIES 
 Flavonoids and stilbenes have attracted great attention as potential 
pharmaceuticals. Up to date more than 5000 natural flavonoid derivatives have been 
isolated from natural resources. Flavonoids are most commonly known for their anti-
oxidant activity. Additionally they might show various biological activities such as 
antibacterial, antiviral, anti-fungal, topoisomerase I and telomerase inhibitors, 
antiangiogenesis etc. Stilbenes are another class of compounds, which are also isolated 
from natural sources having anti-cancer, anti-inflammatory, blood sugar lowering and 
beneficial cardiovascular activities. 
 In this study, synthesis of stilbene fused chalcone and stilbene fused flavanone 
systems were aimed. By means of that, it might be possible to produce a compound 
which can be used for at least two different biological activity or they might show a 
single activity with a great enhancement.  
 For this purpose, a series of chalcone, flavanone, stilbene, stilbene fused 
chalcone, and stilbene fused flavanone derivatives were synthesized. Synthesis of 
stilbene fused chalcones and stilbene fused flavanones were accomplished by two 
different pathways. Two small combinatorial libraries of stilbene fused chalcones and 
stilbene fused flavanones have been built starting from four different acetophenones and 
four different styrenes. Preliminary anti-tumor activities of selected examples against 
human mammary adenocarcinoma cells (MCF-7) and human prostate cancer cell lines 
(PC3) were also evaluated. 
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ÖZET  
 
STĠLBEN KAYNAġTIRILMIġ ÇALKON VE FLAVANON 
TÜREVLERĠNĠN TÜMLEġĠK KÜTÜPHANELERĠ: 
SENTEZ VE ANTĠ-PROLĠFERATĠF ÖZELLĠKLER 
 Flavonoidler ve stilbenler potansiyel ilaç olma özelliklerinden dolayı büyük ilgi 
çekmiĢlerdir. Günümüze kadar doğal kaynaklardan izole edilmiĢ beĢ binden fazla 
flavonoid tanımlanmıĢtır. Flavonoidler genellikle antioksidan özellikleriyle 
bilinmektedirler. Bunun yanında antibakteriyel, antiviral, mantarları yok eden, 
topoizomeraz I ve telomeraz inhibitörleri olarak ve kanser çevresindeki yeni damar 
oluĢumlarının engellenmesi gibi çeĢitli biyolojik aktiviteler gösterebilmektedirler. 
Stilbenler de doğadan izole edilen ve antikanser, kan Ģekerini düĢürücü, iltihap giderici 
ve kalp ve damar hastalıklarına karĢı aktiviteleri olan diğer bir grup bileĢiklerdir. 
 Bu çalıĢmada stilben kaynaĢtırılmıĢ çalkon ve stilben kaynaĢtırılmıĢ flavanon 
sistemlerinin sentezleri amaçlanıĢtır. Bu sayede en az iki farklı biyolojik aktiviteye 
sahip ya da tek bir biyolojik aktiviteyi büyük bir potansiyel ile gösterebilen maddelerin 
üretilmesi beklenmektedir. 
 Bu amaçla, bir seri çalkon, flavanon, stilben ve stilben kaynaĢtırılmıĢ çalkon ve 
flavanonların sentezi tamamlandı. Bu maddeler arasından, stilben kaynaĢtırılmıĢ 
çalkonlar ile stilben kaynaĢtırılmıĢ flavanonlar iki farklı yöntemle sentezlendi. Dört 
farklı asetofenon ve dört farklı stirenden baĢlanarak, stilben kaynaĢtırılmıĢ çalkonlar ve 
stilben kaynaĢtırılmıĢ flavanonlardan oluĢan iki küçük kombinatoryal kütüphane 
oluĢturuldu. Bu kütüphanelerden seçilen bazı örnek bileĢiklerin meme kanseri hücre 
hattı (MCF-7) ve prostat kanseri hücre hattına (PC3) karĢı antitümör aktiviteleri 
değerlendirildi.  
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1 
CHAPTER 1  
 
INTRODUCTION  
 
 Cancer is a group of diseases which is characterized by unregulated cell growth, 
invasion or spread of cells from the site of origin (or primary site) to other sites in the 
body. Cancer cells are characterized by six hallmarks; growth signal autonomy, evasion 
of growth inhibitory signal, evasion of apoptosis, unlimited replicative potential, 
angiogenesis, invasion and metastasis. (Hanahan and Weinberg, 2000) Each hallmark 
distinguishes cancer cells from normal cells by the following statements. 
- Growth signal autonomy: Normal cells acquire external growth factors to divide, 
whereas cancer cells are not dependent on this external stimulus. 
- Evasion of growth inhibitory signals: Normal cells response to inhibitory signals to 
provide their growth blockage. However cancer cells do not respond to inhibitory 
signal, so cancer cells become immortal. 
- Evasion of apoptosis: Apoptosis is defined as programmed cell death. A normal cell 
can end its life by apoptosis if there is irreversible damage, but cancer cells evade 
apoptotic signals. 
- Unlimited replicative potential: Normal cells have a device which defines a finite 
number of cell doublings. This cellular counting device is shortening the chromosomal 
ends, telomeres that occur during every round of DNA replication. However cancer cell 
maintain the length of telomeres. Unlimited replicative potential caused by the altered 
regulation of telomere maintenance. 
- Angiogenesis: Normal cells depend on blood vessels to supply oxygen, and the 
vascular architecture is more or less constant in adult‘s body. However, cancer cells 
induce angiogenesis which is the formation of new blood vessels to help carrying more 
foods to survive and expand. 
- Invasion and metastasis: Normal cells maintain their location in body, and they do not 
change their place. Although the mechanism is not well understood, cancer cells can 
migrate to other parts of the body and this circumstance can be the major cause of death 
of cancer patients. (Pecorino 2005) 
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 There can be many factors which can be blamed for the formation of cancers 
such as tobacco, radiation, chemicals or infectious organisms which are external factors. 
Also there are some internal factors like inherited mutations, hormones, and immune 
conditions. These factors may act together or in sequence, can initiate or promote 
carcinogenesis. Today there are many different cancer treatment strategies. For example 
cancer is treated by surgery, chemotherapy, biological therapy, hormone therapy, 
radiation and targeted therapy. (American Cancer Society 2009)  
 Chemotherapy is the treatment of cancer by pills, containing chemical 
ingredients. These drugs might be taken before or after surgery. Drugs might be taken 
with other type of therapy (e.g. radiotherapy) or alone. Patient may get chemotherapy 
once a day, once a week, or even once a month, depending on the type of cancer the 
patient has and the medicine the patient is taking. The length of the chemotherapy 
depends on the type of cancer, and how she/he responds to the drugs. (American Cancer 
Society) 
 Many useful drugs have been discovered from various plants and they are 
excellent sources for the treatment of many diseases, and cancer is one of them. There 
are many therapeutic agents to treat cancer, which are synthetic or semi-synthetic. 
Beside, many naturally occurring biologically active compounds were also identified 
and clinically used against cancer. Natural products or their semi-synthetic analogues 
constitute approximately 74% of all new chemical entities marketed as anticancer drugs 
between 1981 and 2006. (Newman and Cragg 2007) For this reason, in the war with 
cancer, isolation, synthesis and evaluation of the new compounds against cancer is one 
of the important tools.  
 Flavonoids (1) and stilbenes (2) are among the best known natural products 
which may possess a wide range of biological activity. Because of their valuable role in 
biological systems more than 5000 flavonoid derivatives either were isolated from 
natural products or synthesized in laboratories. 
 
 
 
 
Figure 1.1. Basic flavonoid (1) and stilbene (2) structures. 
O
1 2
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 Flavonoids (1) are class of compounds which are secondary metabolites of 
plants. (Figure 1.1) They are best known for their antioxidant activity. Beside their 
antioxidant activity they have other health benefits, and they can help to reduce the risk 
of having diseases like cancer and heart disease. 
 Flavonoids are derived from the two basic metabolites malonyl-CoA and p-
coumaroyl-CoB. Three molecules of malonyl-CoA and one molecule p-coumaryl-CoB 
produce secondary metabolite chalcone (3) intermediate which can be classified as a 
member of flavonoids. Chalcones have 2 phenolic rings and open three carbon chains. 
Intramolecular cyclization of the chalcone (3) gives another member of flavonoid class 
of substance named as flavanone (4). Then a series of enzymatic modifications occur to 
yield dihydro-flavonols (5), leuco-anthocyanins (6), antho-cyanidins (7), antho-cyanins 
(8), flavones (9), flavonols (10), flavan-3-ols (11,12) and some other phenolics. 
(Figure1.2) 
 
 
 
 
 
 
 
 
Figure 1.2. Biological pathways for the biosynthesis of flavonoids. 
 In 1995, Linuma and co-workers isolated six interesting compounds, 
alopecurones A-F (14-19), from the extracts of the roots of Sophora alopecuroides. 
These compounds were classified as flavanostilbenes because they are composed of 
flavanones condensed with stilbene. (Linuma, et al. 1995) 
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Figure 1.3. Six flavanostilbenes isolated from the Sophora alopecuroides (14-19). 
 Antibacterial activity of three isolated flavanostilbenes (alopecurones A-C, 14, 
15, 16) evaluated on the strains of Stphylococcus aureus which are known for their 
methicillin-resistant property. Results showed that flavanostilbenes uniformly inhibited 
the growth of 21 strains of Stphylococcus aureus with minimum inhibitory 
concentrations in the range of 3.13-6.25 µg/ml. (Sato, et al. 1995) 
 In pharmaceutical industry, design and synthesis of dual acting drugs, dual 
acting enzyme inhibitors are very important. There are several advantages to define 
such compound which inhibits two different enzyme rather than two compounds 
instead, one compound for each enzyme. 
 First of all, with two drugs, two separate synthesis, two formulations and two 
separate metabolism studies will be necessary. Second, two drugs may have different 
pharmacokinetics rates and metabolic profiles so it might be difficult to adjust the 
concentrations to optimum in the same time intervals. Third, the changes that both drugs 
would progress to the clinic at the same rate are small. Fourth, number of clinical trials 
and safety studies for both compounds will be expensive. Lastly, the probability for a 
single drug just starting clinical trials to be afforded for the drug market is 1:10, 
probability for two compound is 1:100. (Silverman 2004) 
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 As it is mentioned above, polyphenols such as flavonoids and stilbenes have 
variety of biological activities. Somehow, sophora alopecuroides combined these two 
functional groups in the same structure, which possess antibacterial property. In these 
structures the double bond and the planarity of the stilbene get lost, and it might be 
highly possible that biological systems might not recognize this part of molecule as 
stilbene anymore. 
 In this work, it is aimed to combine (to fuse) the stilbene structure into either to a 
chalcone or a flavanone without any lost in their structural features. By means of this, 
target molecules can carry the biological properties of stilbene-flavanones, or stilbene-
chalcones at the same time. (Figure 1.4) 
 
 
 
 
Figure 1.4. Proposed structures of stilbene fused chalcones (20) and flavanones (21). 
 To better understand the importance of the analogues, it is necessary to look at 
the biological activities of chalcones, stilbenes and flavanones separately. Rest of the 
introduction will discuss the biological activities and synthesis methodologies of these 
structures. Although it is not possible to list all of these compounds and their biological 
activities, few of them will be represented as a short summary. 
 
1.1 Chalcones  
 
 Chalcone (3) is an aryl styryl ketone that forms the central core for a variety of 
important biological compounds. Chalcones are secondary metabolites of terrestrial 
plants, and precursor for the synthesis of flavonoids. They can be isolated from many 
different plants. In literature plenty of studies exist showing the isolation of the 
chalcones from natural sources. (Adesanwo, et al. 2009, Van Puyvelde, et al. 1989). 
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1.1.1. Biological Activities of Chalcones  
 
1.1.1.1. Anti-invasive Activity  
 
 Invasion is one of the hallmarks of malignant tumours and generally leads to 
metastasis, which is the major cause of cancer death. Anti-invasive property of chalcone  
1-[2-hydroxy-3-(3-methyl-2-butenyl)-4,5,6,-trimethoxyphenyl]-3-(3-bromophenyl) 
propenone (22), was investigated against human MCF-7/6 mammary carcinoma cells. 
(Figure 1.5) It is found to be effective in inhibiting the invasion of cancer cells onto 
normal cells at 10 µM concentration, which makes it as a lead compound for further 
studies to design new analogues showing anti-invasive activity. (Mukherjee, et al. 2001) 
 
 
 
 
  
Figure 1.5. Structure of 1-[2-hydroxy-3-(3-methyl-2-butenyl)-4,5,6,-trimethoxyphenyl]-
3-(3-bromophenyl)propenone (22). 
 
1.1.1.2. Antimalarial Activity  
 
 Nowadays malaria is again becoming a health problem to deal with because of 
the development of resistance by lethal causative parasitic species, plasmodium 
falciparum to the drugs. Boyom et al. isolated bartericin A (23), stipulin (24), 4-
hydroxylonchocarpin (25) from Dorstenia barteri var. subtriangularis, and compound 
23, 24 and 25 were evaluated for their antimalarial activity in vitro against P. 
Falciparum and it is found  that they are all effective against malaria with IC50 values of 
2.15, 5.13 and 3.36 µM, respectively. (Boyom, et al. 2007) 
 A similar study was done by Mishra et al. A series of chalcone derivatives were 
synthesized and tested against human malarian parasite and plasmodium falciparum in 
vitro. Among the tested compounds, chalcones 26-28 were the most active compounds 
with the IC50 values 2.93, 2.5 and 1.50 µM respectively. (Mishra, et al. 2008)  
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Figure 1.6. Anti-malarian active chalcone derivatives, bartericin A (23), stipulin (24), 4-
hydroxylonchocarpin (25) and other chalcones (26-28).  
 
1.1.1.3. Antibacterial Activity  
 
 Tuberculosis is a disease caused by Mycobacterium tuberculosis which is the 
main fatal infectious diseases that mainly infect women of reproductive age. 
Licochalcone A is one of the naturally occurring chalcone that inhibits the 
Mycobacterium tuberculosis, Mycobacterium bovis, Mycobacterium kansasii, 
Mycobacterium marinum and Mycobacterium xenophii with MIC < 20 mg/L. 
(Nowakowska 2007) 
Figure 1.7. Structure of licochalcone A showing antibacterial activity. 
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1.1.1.4. Trypanocidal Activity   
 
 Trypanosoma cruzi is a parazite which causes sleeping sickness. Many 
derivatives of chalcones were synthesized by Lunardi et al. and tested against anti-
trypasomes activity. Unsubstituted chalcone (3) was found to be the most active 
compound with IC50 at 24.8 µM. (Lunardi, et al. 2003) 
 Figure 1.8. Structure of chalcone (3) showing trypanocidal activity. 
 
1.1.1.5. Antileishmanial Activity  
 
 Leishmanial is an infectious disease that affects millions of people. Fröhner and 
co-workers synthesized sulphonamide derivatives of 4-methoxychalcone and tested for 
their antileishmanial activities to overcome unsatisfactory treatment protocols.(Figure 
1.9) Results showed that compound 30 is the most active sulphonamide chalcone 
derivative, and all tested sulphonamide chalcones show higher activity compared to 
their chalcone equivalent 4-methoxychalcone (31). IC50 values for compounds 30 and 
31 are 3.5 µM and 16.6 µM respectively. (Fröhner, et al. 2009) 
 
 
 
 
 
 
Figure 1.9. Structures of 4-methoxy-sulfonamidechalcone (30) and 4-methoxychalcone 
(31). 
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1.1.1.6. Antiviral Activity  
 
 Virus infectious can cause many diseases. Antiviral acting compounds can be 
useful in the treatment of these diseases. AIDS is one of the fatal diseases caused by 
HIV (human immunodeficiency virus). Wu et al. demonstrated that compound 32 
showed potent anti-HIV activity. (EC50 = 0.022 µg/ml) Beside this, Uchiumi et al. 
found that licochalcone A (29), licochalcone B (33) and tetrahydroxymethoxychalcone 
(34) have transcription suppression effect on HIV promoter region. (Uchiumi, et al. 
2002) 
 
 
 
 
 
 
 
Figure 1.10. Structures of antiviral chalcones: (29 and 32-34). 
1.1.1.7. Anticancer Activity  
 
 In literature large number of chalcones were synthesized and evaluated for their 
possible anticancer activity. As an example, Modzelewska and colleagues synthesized 
several chalcone and bis-chalcone derivatives. (Figure 1.11) Antiproliferative properties 
of three bis-chalcones 35-37 were evaluated on the wild type of MCF-7 breast cancer 
cell lines at nanomolar concentrations. Especially compound 37 has IC50 value at 350 
nM. (Modzelewska, et al. 2006) 
 Another similar study was carried out by Lee and colleagues. They evaluated the 
antitumor activity of 2'-hydroxy-4'-methoxychalcone (38) in vivo and in vitro. It is 
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O ClOH
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39
found that, compound 38 shows antiproliferative activity on cultured pulmonary artery 
endothelial cell lines and its IC50 concentration was found as 12.7 µM. (Lee, et al. 2006) 
 
Figure 1.11. Structures of chalcones (35-38) having antiproliferative properties. 
 
1.1.1.8. Antiangiogenic Activity  
 
 Angiogenesis is formation of new blood vessels and it is essential for a cancer 
cell to survive. The inhibition of angiogenesis is important to prevent proliferation of 
cancer cells. Nam et al. synthesized 2',5'-dihydroxychalcones and evaluated its 
cytotoxicity on different tumor cell lines. Among the tested compounds the most 
effective one was (E)-3-(2-chlorophenyl)-1-(2,5-dihydroxyphenyl)prop-2-en-1-one (39) 
on A431 human epidermoid carcinoma cell lines, with IC50 concentration at 0.03 
µM.(Figure 1.12) This compound also exhibited strong inhibitory effects on the 
HUVEC tube formation in an in vitro model. When administered into BDF1 mice 
bearing Lewis lung carcinoma cells at 50 mg/kg.day, 39 was found to inhibit the growth 
of tumor mass by 60.5%. (Nam, et al. 2003) 
Figure 1.12. Structure of 2-chloro-2',5'-dihydroxychalcone (39). 
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1.1.1.9. Antimicrobial Activity 
 
 Mbaveng et al. evaluated the antimicrobial activity of crude extracts of 
Dorstenia barteri. Isobavachalcone (40) and kanzonol C (41), isolated from crude 
extract, prevented the growth of all tested microorganisms effectively. (Figure 1.13) 
(MIC value of 0.3 µg/ml for compound 40 on the six bacteria of tested twenty-two.) 
(Mbaveng, et al. 2008) 
 
 
 
 
Figure 1.13. Structures of isobavachalcone (40) and kanzonol C (41). 
 
1.1.2. Synthesis of Chalcones  
 
 There is a huge library of chalcones in literature either isolated from nature or 
synthesized by a chemist in a laboratory. There are variety of methods to synthesize 
chalcones in literature. Base catalyzed Claisen-Schmidt condensation is the most widely 
used method and mostly carried out in the presence of strong bases such as NaOH, 
Ba(OH)2 and KOH.  
 A series of chalcones (3, 50-55) and 2-hydroxychalcones (57-63) have been 
synthesized by Cabrera et al., starting from acetophenone and substituted benzaldehyde 
via base catalyzed aldol condensation. In the process, acetophenone or 2-
hydroxyacetophenone was reacted with corresponding aldehydes. Chalcone derivatives 
(Figure 1.14.) and 2-hydroxychalcone derivatives (Figure 1.15.) having substitution on 
ring B, were prepared starting from substituted benzaldehyde in high yields. (Cabrera, et 
al. 2007) This method can tolerate wide range of substituents on the aryl rings.  
Figure 1.14. Synthesis of chalcone derivatives (3, 50-55) under basic conditions. 
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Figure 1.15. Synthesis of 2-hydroxychalcone derivatives (57-63) under basic condition.  
 
 In 1990, Toda et al. has worked on the aldol condensation in the absence of 
solvent. They observed that in solvent free condition some aldol reactions proceeded 
more efficiently. Acetophenone (42) and 4-chlorobenzaldehyde (58) were grinding in 
the presence of NaOH by pestle and mortar to give chalcone 50 with 98% yield. (Toda, 
et al. 1990) 
 
 
Figure 1.16. Synthesis of chalcone derivative (50) in the absence of solvent under basic 
conditions. 
 
 Acid catalyzed Claisen-Schmidt condensations are also useful reactions to 
prepare chalcones. AlCl3, HCl, TiCl4 are well known catalysts in these reactions. A 
similar acid catalyzed reaction was developed by Narender and Reddy. (Figure 1.17) 
Borontrifluoride-etherate complex was used as Lewis acid. It is known that, reaction 
time is long (2-3 days) and side reaction probability is high in hydroxide catalyzed 
reactions. Contrarily very short reaction times and very high reaction yields were 
reported for BF3-Et2O catalyzed Claisen-Schmidt reactions. No side reaction was 
observed. Also there are other advantages of this method, such as solvent–free reaction 
can occur in liquid reactants. BF3-Et2O can tolerate the presence of amine and ester 
functionalities, and chalcones can be synthesized in high yields. In summary this 
method is also very efficient for chalcone synthesis. (Narender and Reddy 2007) 
 
 
Figure 1.17. Synthesis of chalcone (3) catalyzed by BF3-Et2O. 
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 In another work, L-proline was utilized as an organocatalyst for the synthesis of 
substituted chalcones and flavanones. Chalcones and flavanones were formed 
simultaneously in this method. Procedure is very simple, 2-hydroxyacetophenone 
derivatives (56, 64, 65) and benzaldehyde (43) were stirred in the presence of L-proline 
(30 mol %) in DMF (0.02 M) at 80 oC for 18 h. After the usual work up and 
chromatography, chalcones (57, 66, 67) were furnished. (Figure 1.18) (Chandrasekhar, 
et al. 2005) 
Figure 1.18. L-proline catalyzed synthesis of chalcones (57, 66, 67). 
 As an another interesting study, Comisar and Savage studied on crossed aldol 
condensation in high-temperature water (HTW). High-temperature water (HTW) is 
defined as liquid water above 200 oC.  Benzaldehyde (43) and acetophenone (42) was 
reacted at 200 oC, 250 oC, and 300 oC and the maximum yield of chalcone (3) was 
reported as 21% at 250 oC after 15 hours of reaction time. (Figure 1.19) (Comisar and 
Savage 2004) 
 
 
  
Figure 1.19. High-temperature of water (HTW) catalyzed synthesis of chalcone (3). 
 
 Alternatively, bamboo char sulfonic acid, a novel solid catalyst, was prepared 
and used in the synthesis of chalcones under solvent free conditions. (Figure 1.20) 
Yields of reactions were relatively high. (60-82%) (Xu, et al. 2008) 
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Figure 1.20. Synthesis of chalcone (3) in the presence of bamboo char sulfonic acid. 
 
1.2. Flavanones  
 
 Flavanones (4) are one of the subclasses of flavonoids, having strong antioxidant 
activity and generally formed by intramolecular Michael addition type cyclization of 2-
hydroxychalcones. (Figure 1.21) 
  
   
  
 Figure 1.21. 2-hydroxychalcone (57) as precursor of flavanone (4). 
 Like chalcones, flavanones also have variety of biological activities, such as 
antileukemia, antibacterial, aromatase inhibitor activity. These biological activities will 
be discussed in the following sections. 
 
1.2.1. Biological Activities of Flavanones 
 
1.2.1.1. Antileukemia Activity  
 
 Qiaojun He et al. demonstrated that newly synthesized flavanone derivative 2-
(2-chloro-4-(methylsulfonyl)phenyl)-4-(4-chlorophenyl)-3,4-diethoxy-3,4-dihydro-2H-
chromeno[4,3][1,2,3]thiadiazole  (MSFTZ, figure 1.22) (68) inhibits the proliferation of 
leukemia cells. It is also shown that MSFTZ induces apoptosis in HL-60 leukemia cells 
with IC50 value of 1.60 µM. (He, et al. 2006) 
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Figure 1.22. Structure of MSFTZ (68). 
 
1.2.1.2. Antibacterial Activity  
 
 Sepicanin A (Figure 1.23) is a flavanone which is isolated from Artocarpus 
sepicanus. Sepicanin A showed significant selectivity against methillicin–resistant 
Staphylococcus aureus (MRSA) with IC50 concentration at 1.4 µM and MIC at 2.9 µM. 
(Radwan, et al. 2009) 
 
  
 
Figure 1.23. Structure of  sepicenin A (69). 
 
1.2.1.3. Aromatase Inhibitory Activity 
 
 Aromatase is an enzyme and plays an important role in development of breast 
cancer. For that reason it is important to develop aromatase inhibitors to treat the breast 
cancer. Structures of two new benzophenone derivatives of flavanone (70,71) are shown 
in figure 1.24. Activities of these two compounds were reported as nine times more 
potent than aminogluthetimide which was the first clinically used aromatase inhibitor. 
(IC50 = 0.61 µM for compound 70 and IC50 = 0.63 µM for compound 71). (Yahiaoui, et 
al. 2007) 
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Figure 1.24. Derivatives of 7,8-benzoflavanones (70,71) as potent aromatase inhibitors. 
 
1.2.1.4. Anticancer Activity 
 
 One of the well known biological activities of flavanones is anticancer activity. 
There are known isolated and synthetic flavanones which show potent anticancer 
activity.  Peng et al. isolated six flavanones from the leaf of Patrinia villosa Juss, and 
evaluated their anticancer activities in vitro. Three of them (72, 73, 74) exhibited strong 
anticancer activity to K562 (human erythromyeloblastoid leukemia), HT29 (human 
colon adenocarcinoma) and MCF7 (human breast adenocarcinoma) cell lines. (Figure 
1.25) Reported IC50 values of compound 72 against tested cancer cell lines were 1.64, 
2.42 and 3.04 µM respectively. Those values for compound 73 were 4.08, 5.28 and 4.26 
µM, and for compound 74 were 5.72, 7.94 and 7.62 µM respectively. (Peng, et al. 2006) 
  
 
 
 
 Figure 1.25. Structures of flavanones isolated from Patrinia villosa Juss. 
 
1.3.1.5. Metastasis Inhibition Activity  
 
 Beside anticancer activity metastasis inhibition effects of flavanones were also 
reported in literature. (Hsiao, et al. 2007) Antiproliferative activity and metastasis 
inhibition potential of flavanone (4) and 2'-hydroxyflavanone (75) were 
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evaluated.(Figure 1.26) Tested compounds show little influence on cell viability, but 
inhibit the invasion and metastasis of A549 cells.  
 
 
 
Figure 1.26. Structures of flavanone (4) and 2'-hydroxyflavanone (75). 
 
1.3.1.6. Chemoprevention Activity 
 
 Silibinin (76) is a flavanone which is isolated from the fruits of milk thistle. 
(Figure 1.27) It has strong anticancer efficacy against human androgen-dependent and 
independent human prostate carcinoma cell cultures. (Zi, et al. 1998, Zi, et al. 1999) 
Silibinin strongly inhibits cell growth and DNA synthesis, and cause apoptotic cell 
death in rat prostate cancer cell. (Tyagi, et al. 2002) 
 
 
 
 
 
 
 
Figure 1.27. Structure of silibinin (76). 
 
1.3.1.7. Antioxidant Activity 
 
 Antioxidants play important roles to protect the cells being damaged from 
radicals. Chronic disease (cancer or heart disease) risks can be reduced by taking 
antioxidants. (Stanner, et al. 2003) 
 Hesperidin (77) has a disaccharide attached flavanone structure, and it shows 
strong antioxidant activity with IC50 concentration at 11 µM.(Figure 1.28) (Rao, et al. 
2003) 
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Figure 1.28. Structure of hesperidin (77) as an example of antioxidant flavanone. 
 
1.3.2. Synthesis of Flavanones 
 
 It was mentioned that flavanones can be prepared from chalcones by Michael 
addition type cyclization reaction. Cyclization can be done under either acidic or basic 
catalyst. In literature, biosynthetic pathways are also reported for this transformation. 
Different approaches toward the asymmetric syntheses of flavanones are also present. 
Reactions, giving flavanone structures, will be discussed briefly in this section. 
 One of the simplest transformations of 2-hydroxychalcones to flavanone is 
refluxing in glacial acetic acid as remarked by Cabrera and colleagues. (Cabrera, et al. 
2007)(Figure 1.29) 
 
 
 
Figure 1.29. Acid catalyzed synthesis of flavanone (4) starting from 2-hydroxychalcone 
(56). 
 
 As discussed in chalcone synthesis L-proline is an effective catalyst for the 
Claisen-Schmidt reaction. In this reaction flavanones were reported as major 
products.(Figure 1.30) The ratios of flavanones to chalcones changes by the reactants 
but roughly it gives 7:3 mixtures of flavanone and chalcone. (Chandrasekhar, et al. 
2005) 
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Figure 1.30. L-proline catalyzed synthesis of flavanone (4). 
 
 Asymmetric cyclization of 2'-hydroxychalcone to flavanone is enzyme-catalyzed 
step in biosynthesis of flavonoids. This reaction occurs easily by enzyme catalyst, but it 
is quite difficult to perform same reaction with a non-enzyme catalyst. There are studies 
to develope such catalysts in the literature. For example cinchona alkaloids used as a 
chiral Bronsted base catalyst for such asymmetric cyclization reaction. (Figure 1.31) 
Cinchonine (CN), cinchonidine (CD), quinine (QN), and quinidine (QD) were also used 
as asymmetric catalyst for cyclization of 2-hydroxychalcones, and up to 64% 
enantiomeric excess was observed in these trials. (Dittmer, et al. 2007) 
 
 
  
Figure 1.31. Example for asymmetric synthesis of flavanone (79). 
 
 Katsuyama et al. synthesized flavanones in Esherichia coli. (Figure 1.32) Their 
artificial biosynthetic pathway includes: p-coumaroyl (80) synthesis from p-coumaric 
acid (81) by coenzyme A ligase (4CL), and chalcone (82) synthesis from p-coumaroyl 
by chalcone synthase enzyme (CHS), then synthesis of asymmetric (2S) flavanones (83) 
from chalcones by chalcone isomerise (CHI). (Katsuyama, et al. 2007) 
O
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Figure 1.32. Artificial biosynthetic pathway for the synthesis of flavanone (83), reported 
by Katsuyama. 
 
 Syntheses of flavanones under solvent-free conditions were performed by 
Sagrera et al. by using microwave irradiation of chalcones. Reactions were carried out 
in unmodified household microwave oven. Irradiation of chalcones with 30% 
trifluoroacetic acid over silica gel furnished flavanones in high yields. (Sagrera, et al. 
2005) 
  
 Figure 1.33. Microwave accelerated synthesis of flavanones (4).  
 
1.3. Stilbenes 
 
 Stilbenes (diarylethenes) are a class of biologically active components, isolated 
from nature that possesses various medicinal properties. Two isomers of stilbene exist, 
which are (E)-stilbene (84) and Z-stilbene (85). (Figure 1.34) 
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Figure 1.34. Structures of (E)-stilbene (84) and (Z)-stilbene (85). 
 
 The most famous stilbenes are resveratrol (86) and combretastatin A-4 (87). 
Both molecules are naturally occurring, and biologically active compounds. (Nam 
2003) 
Figure 1.35. Structures of resveratrol (86) and combretastatin A-4 (87). 
 
1.3.1. Biological Activities of Stilbenes 
 
1.3.1.1. Antioxidant Activity  
 
 Stilbenes, well known for their antioxidant activity, are found in grapes, red 
wine, berries, and peanuts. Many studies were done on this subject, for example Jun and 
co-workers recently synthesized trans-stilbene derivatives and evaluated their anti-
oxidant activities. Among the synthesized molecules, an amine derivative of stilbene 
(88) shows three times more potent antioxidant activity than resveratrol does. (Jun, et al. 
2009, figure 1.36) 
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Figure 1.36. Structure of (E)-4-(3,4-bis(2-fluorobenzylaminooxy)styryl)benzaldehyde 
(88). 
 
1.3.1.2 Antitumor Activity 
 
 Three stilbene derivatives, (resveratrol (86), piceatannol (89), and cassigarol A 
(piceatannol dimer) (90)) were isolated from the medicinal plants and inhibited tumor 
growth and metastasis through the inhibition of tumor-induced angiogenesis. (Kimura, 
et al. 2000, 2000, 2001) 
Figure 1.37. Stilbenes showing antitumor properties: piceatannol (89), cassigarol A 
(90). 
 
1.3.2 Synthesis of Stilbenes 
 
 There are many reactions to form double bond functionality, and Wittig reaction 
is one of them.(Figure 1.38) Wittig reaction of phosphonium bromide (91) with 
benzaldehyde in THF in the presence of sodium hydride yields cis and trans-stilbene 
together, and cis-stilbene is the major product (66%) for this reaction. (Cushman, et al. 
1991) 
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Figure 1.38. Synthesis of trans (84) and cis (85) stilbene by Wittig reaction. 
 
 Similarly, trans stilbene can be synthesized by Wittig-Horner reaction of 
phosphonate ester (92) with benazaldehyde in the presence of sodium methoxide as 
base and DMF as solvent with 87% yield.(Cushman, et al. 1991) 
Figure 1.39. Synthesis of trans-stilbene (84) by Wittig-Horner reaction. 
 
 Stilbenes can also be synthesized by biosynthesis. As shown Figure 1.40. 
Hatsuyama and colleagues synthesized stilbenes from p-coumaroyl-CoA by stilbene 
synthase enzyme (STS). (Katsuyama, et al. 2007) 
 
 
 
Figure 1.40. Synthesis of resveratrol (86) via biosynthetic pathway. 
 
 As an alternative, it is shown that trans isomer of combretastatin A-4 can be 
synthesized by using palladium catalyzed Suzuki cross coupling reaction of (E)-5-
(2'Bromoethenyl)-2-methoxyphenol and 3,4,5-trimethoxybenzeneboronic acid. 
(Gaukrager, et al. 2001) 
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Figure 1.41. Synthesis of trans-combretastatin A-4 (95) by Suzuki cross coupling 
reaction. 
 
 The last example for the synthesis of trans-stilbene derivatives is ligand-free 
palladium catalyzed Heck reaction of bromobenzene with styrene (Figure 1.42). In this 
method, Vries and colleagues used very low amount of palladium acetate in N-methyl 
pyrollidone, and synthesized trans-stilbene at high yields. (Vries, et al. 2003) 
 
 
 
 Figure 1.42. Synthesis of trans-stilbene (84) by Heck reaction.  
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CHAPTER 2  
 
RESULTS AND DISCUSSIONS 
 
2.1. Toward the Synthesis of Stilbene Fused Chalcones and Flavanones 
 
 Pharmaceutical sciences need to develop compounds which show strong 
biological activity. The other important parameter is the availability of that compound. 
Biologically active compounds having complex structures, whose synthesis require 
large numbers of steps, consumes huge amount of time and resources. 
 On the other hand to develop biologically active compounds, synthesized by few 
step, is very important. By means of this, amount of time and resources spent to carry 
biologically active compound to the market could be much lower. 
 Flavanones, chalcones and stilbenes are relatively simple molecules and can be 
synthesized in one or maximum two steps, so preparing them in large quantities are not 
a big deal. As it is noted in introduction part, main aim of this thesis is to prepare the 
stilbene fused chalcones and flavanones, which are relatively simple molecules. 
 Retrosynthetic analyses of target molecules are shown in figure 2.1. Synthesis of 
either stilbene fused chalcone or stilbene fused flavanone can simply be enough, 
because one of them can be converted to other one in the presence of acids or bases. 
 It might be possible to synthesize stilbene fused chalcones and flavanones by 
two different routes. Both routes require Claisen-Schmidt reaction, Michael addition 
and Heck reaction steps. Only difference is the order of the reactions. In route A, 
chalcone synthesis is planned at the beginning then it will be converted to flavanone and 
finally stilbene will be fused to flavanones by Heck reaction. 
 Contrarily in route B Heck reaction is the first reaction, then formed stilbene will 
be transformed into chalcones and flavanones in the next steps. 
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Figure 2.1 Retrosynthetic analysis of stilbene fused chalcone and flavanone system. 
 
 The main difference between the routes is limitation of the possible conditions 
for cyclization reaction of route B. Double bonds are kind of sensitive towards acids so 
using an acid catalyst might not be good in cyclization step of route B. On the other 
hand at Route A Heck reaction may cause a problem because it is well known that α,β- 
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unsaturated ketones are good substrates for Heck reactions. It is well known that Heck 
reaction should be carried out under basic condition which will cause an equilibrium 
reaction between flavanone and chalcone. Later chalcone can be a substrate for a self 
Heck reaction under basic conditions. By keeping these in mind, trials for the synthesis 
of target molecules started by route A. 
 
2.2 Route A: Heck Reactions of Flavanone Derivatives 
 
 Commercial available 3-bromobenzaldehyde has been chosen as a cornerstone in 
this work. It has the functionalities for both Heck and aldol condensation reactions. By 
keeping it still, different 2-hydroxyacetophenones are tried for aldol condensation 
reactions in sodium hydroxide containing ethanol at room temperature. 
 As it is listed in table 2.1 reactions gave the chalcone products in high yields 
(90-93%). All acetophenones, used in these trials, have electron donating substituents 
except entry 2. 
 A similar aldol condensation reaction was also tried in the presence of L-proline 
as catalyst (entry 6). This reaction gave 15% chalcone with 21% flavanone products. 
Although acetophenone has electron withdrawing group, yield was lower than expected 
in this trial. Hence L-proline catalyst was abandoned.  
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Table 2.1. Synthesis of chalcone derivatives (110-115). 
 
Entry 
Acetophenone 
Conditions Product 
Yield 
(%) R1 R2 R3 R4 
 
1 
 
2 
 
3 
 
4 
 
5 
 
6 
 
H 
 
H 
 
OCH3 
 
OCH3 
 
H 
 
H 
 
OCH3 
 
Cl 
 
H 
 
H 
 
H 
 
CH3 
 
H 
 
H 
 
OCH3 
 
H 
 
OH 
 
H 
 
H 
 
H 
 
H 
 
H 
 
CH3 
 
NO2 
 
NaOH, EtOH, RT 
 
NaOH, EtOH, RT 
 
NaOH, EtOH, RT 
 
NaOH, EtOH, RT 
 
NaOH, EtOH, RT 
 
L-Proline, DMF, 
800C 
 
110 
 
111 
 
112 
 
113 
 
114 
 
115 
 
90 
 
93 
 
92 
 
91 
 
90 
 
15 
  
 In the second step, cyclizations of 2-hydroxy chalcones with intramolecular 
Michael reactions were studied under acidic and basic conditions. In these attempts, 
first 25 ml of glacial acetic acid were used for each mmol of 2-hydroxychalcone under 
reflux (Table 2.2). Except entry 2, all 2-hydroxychalcones are substituted by electron 
donating groups. All reactions gave the products with very good yields except the 
dimethoxy substituted chalcone case. Although there was not any reasonable 
explanation for this we continued the trials by base catalyzed cyclization reactions. 
Sodium acetate, anhydrous or trihydrate was used as catalyst for cyclization reactions in 
refluxing ethanol. Contrarily to trihyrated one, anhydrous sodium acetate gave product 
with 45% yield. This method was found much more useful compared to acetic acid 
method. Because of easier workup, requirement of small amount of catalyst and cleaner 
TLC results. Anhydrous sodium acetate was chosen as the best suited catalyst for this 
reaction and will be used in the rest of cyclization reactions in this thesis.  
 
 
CH3
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+
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Conditions
18-24 h. OH
OR1
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R4 Br
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Table 2.2. Synthesis of flavanone derivatives (116-120). 
 
Entry 
2-Hydroxychalcone 
Conditions Product 
Yield 
(%) R1 R2 R3 R4 
 
1 
 
2 
 
3 
 
4 
 
5 
 
6 
 
7 
 
H 
 
H 
 
OCH3 
 
OCH3 
 
OCH3 
 
H 
 
OCH3 
 
OCH3 
 
Cl 
 
H 
 
H 
 
H 
 
H 
 
H 
 
H 
 
H 
 
OCH3 
 
H 
 
H 
 
OH 
 
OCH3 
 
H 
 
H 
 
H 
 
H 
 
H 
 
CH3 
 
H 
 
Acetic acid, Reflux 
 
Acetic acid, Reflux 
 
Acetic acid, Reflux 
 
Acetic acid, Reflux 
 
NaOAc, EtOH 
Reflux 
NaOAc.3H2O, EtOH 
Reflux 
NaOAc.3H2O, EtOH 
Reflux 
 
116 
 
117 
 
118 
 
119 
 
119 
 
120 
 
118 
 
79 
 
85 
 
No Rxn 
 
90 
 
45 
 
No Rxn 
 
No Rxn 
 
 In the last step of route A, Heck reactions of synthesized flavanones with 
selected styrenes were performed in the presence of Pd(OAc)2 with or without ligands. 
Previously Li and Wang showed that Heck reaction can successfully produces stilbene 
in a mixture of 1% Pd(OAc)2 in triethanolamine at 100 oC. (Li and Wang 2006) Same 
procedure was applied to the synthesized flavanones in varying amount of palladium 
(II) acetate (entry 1-6). All reactions were monitored by TLC and formations of many 
new spots have been observed in all cases. Among these trials, purification of the 
product was successful for only first reaction after many attempts. (Table 2.3) 
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Table 2.3. Synthesis of stilbene fused flavanones (126-132). 
Entry R R1' R2' Conditions Product  Yield(%) 
 
1 
 
 
2 
 
 
3 
 
 
4 
 
 
5 
 
 
6 
 
 
7 
 
 
8 
 
 
9 
 
OCH3 
 
 
Cl 
 
 
OCH3 
 
 
Cl 
 
 
OCH3 
 
 
OCH3 
 
 
OCH3 
 
 
OCH3 
 
 
OCH3 
 
H 
 
 
H 
 
 
CH3 
 
 
H 
 
 
H 
 
 
H 
 
 
H 
 
 
H 
 
 
H 
 
 
OCH3 
 
 
OCH3 
 
 
H 
 
 
CH3 
 
 
F 
 
 
NH2 
 
 
OCH3 
 
 
OCH3 
 
 
CH3 
 
1% Pd(OAc)2, 
N(C2H4OH)3, 10 h. 
 
0,1% Pd(OAc)2, 
N(C2H4OH)3, 15 h. 
 
1% Pd(OAc)2 / 
N(C2H4OH)3, 14 h. 
 
1% Pd(OAc)2, 
N(C2H4OH)3, 15 h. 
. 
20% Pd(OAc)2, 
N(C2H4OH)3, 48 h. 
. 
4% Pd(OAc)2, 
N(C2H4OH)3, 48 h 
 
1% Pd(OAc)2, 2%P(Ph)3, 
Et3N, CH3CN 24 h. 
 
1% Pd(OAc)2, 2%P(Ph)3, 
Na2CO3, Toluene, 24 h. 
 
1% Pd(OAc)2, 2%P(Ph)3, 
Na2CO3, Toluene, 24 h. 
 
126  
 
 
127  
 
 
128  
 
 
129 
 
 
130 
 
 
131 
 
 
126 
 
 
126 
 
 
132 
 
  
44 
 
 
(Inseparable 
mixture) 
 
(Inseparable 
mixture) 
 
(Inseparable 
mixture) 
 
(Inseparable 
mixture) 
 
(Inseparable 
mixture) 
 
(Inseparable 
mixture) 
 
(Inseparable 
mixture) 
 
(Inseparable 
mixture) 
 Heck reactions of flavanones with styrene were also tried in presence of a ligand 
and a base (entry 7-9). Again all of them produced inseparable mixtures of products. 
For this reason this route was abandoned and further studies were concentrated on route 
B. 
  In these inseparable mixtures no product could be isolated and characterized to 
better understand the reason for the fail of Heck reaction with flavanone. We can only 
speculate that flavanones and chalcones can exist in equilibrium under basic conditions 
and chalcones can be a good substrate for Heck reaction. In such equilibrium α,β-
unsaturated ketones are more active toward Heck reactions than the styrenes. So it is 
O
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possible to form a self Heck reaction of bromine substituted chalcones (Figure 2.2). 
Further similar reactions may produce many additional products.  
  
Figure 2.2. Possible self Heck reaction of chalcone. 
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2.3 Route B: Stilbene Formation as the First Step to Prepare Stilbene 
Fused Chalcone and Flavanone Libraries 
 
 Reaction conditions were almost optimized for aldol reaction and Michael 
Addition in route A experiments. Alkaline ethanol solution was quite suitable for aldol 
reaction, and sodium acetate solution in ethanol gave clear product formation in 
cyclization reaction. Because both conditions are basic, there is no harm to try the 
complete the synthesis starting from a stilbene. 
 On the other hand, it is necessary to optimize the Heck reaction conditions to 
complete the synthesis efficiently. For this purpose, modified Heck reactions, developed 
by Vries and co-workers, were used. This procedure requires only 0.02% palladium (II) 
acetate as catalyst and sodium acetate was used as base. Beside, no ligand was 
necessary. Reactions were carried out for the synthesis of five different stilbenes (133-
137) in N-methyl pyrolidone at 135 oC. Except 4-aminostyrene (125), rest of the 
reactions yielded target stilbenes in high yields (75-93%).  
 
Table 2.4. Synthesis of stilbene derivatives (133-137) under ligand free conditions. 
Entry Styrene R1' R2' Product Yield (%) 
 
1 
 
2 
 
3 
 
4 
 
5 
 
121 
 
122 
 
123 
 
124 
 
125 
 
H 
 
H 
 
CH3 
 
F 
 
H 
 
OCH3 
 
CH3 
 
H 
 
H 
 
NH2 
 
133 
 
134 
 
135 
 
136 
 
137 
 
93 
 
80 
 
90 
 
75 
 
No Rxn 
 
 
Br
O
H
+
R2'
R1'
Pd(OAc)2, NaOAc
NMP, 135 oC
R2'
R1'
O
H
101 121-125 133-137
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 After optimization the Heck reaction it is aimed to produce libraries of stilbene 
fused chalcones and flavanones. Stilbenes, formed from the Heck reactions, were used 
for this purpose. To complete the libraries four different acetophenones (2-hydroxy-5-
methoxy acetophenone (65), 5-chloro-2-hydroxy acetophenone (105), 2-hydroxy-6-
methoxy acetophenone (107) and 2-hydroxy-4-methoxy acetophenone (138)) were 
chosen. Starting materials for these combinatorial libraries were pictured in figure 2.3. 
 
 Figure 2.3. Selected ketones and styrenes for combinatorial libraries. 
 
 To complete the libraries, formed stilbenes were reacted with selected 
acetophenones (65, 105, 107, 138) in alkaline ethanol at room temperature. After 24 
hours, reactions were quenched and products were purified in silica gel column 
chromatography. Isolated yields for these reactions were listed in table 2.5. It seems 
like, some of the yields are relatively low. Difficulty in purification step of formed 
chalcone from the starting materials, especially the acetophenones, was the main reason 
for these lower yields. Products of 2-hydroxy-4-methoxy acetophenone could not be 
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purified completely from acetophenone during silica gel column. Small amount of 
impurity (less than 5 %) were present in NMR spectrum. (Table 2.5) 
 In the last step, stilbene fused chalcones were divided into two parts. One 
portion of each stilbene fused chalcone treated with sodium acetate in ethanol to 
complete the cyclization reactions. Reactions were quenched after 48 hours and 
products were isolated by silica gel column in good yields. For these reactions isolated 
yields were given in table 2.6. Lower yields are resulted from the difficulties during the 
purification in flash chromatography. (Table 2.6) 
 Addition to combinatorial libraries, one more stilbene fused chalcone (139) and 
flavanone (140) were synthesized as shown in figure 2.4. 
 
H
O
OMe CH3
OH
OMe
MeO
O
EtOH, NaOH, r.t.
OH
OOMe
MeO
OMe
NaOAc,
EtOH,
reflux
O
OOMe
MeO
OMe
133 139
140  
Figure 2.4. Synthesis of stilbene fused chalcone (139) and flavanone (140) substituted 
by two methoxy on ring A. 
  
 Aldol reaction of stilbene (133) with 2-hydroxy-4,6-dimethoxy acetophenone 
gave the stilbene fused chalcone (139) with 44% yield. Then it was transformed to 
stilbene fused flavanone (140) with 65% yield. Overall summaries for the libraries of 
stilbene fused chalcones and stilbene fused flavanones were reviewed in table 2.7 and 
table 2.8. 
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Table 2.5. Synthesis of stilbene fused chalcones (141-156). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Entry Stilbene Acetophenone Product Yield (%) 
R1'  R2' R1 R2 R3 
 
1 
 
2 
 
3 
 
4 
 
5 
 
6 
 
7 
 
8 
 
9 
 
10 
 
11 
 
12 
 
13 
 
14 
 
15 
 
16 
 
H 
 
H 
 
CH3 
 
F 
 
H 
 
H 
 
CH3 
 
F 
 
H 
 
H 
 
CH3 
 
F 
 
H 
 
H 
 
CH3 
 
F 
 
OCH3 
 
CH3 
 
H 
 
H 
 
OCH3 
 
CH3 
 
H 
 
H 
 
OCH3 
 
CH3 
 
H 
 
H 
 
OCH3 
 
CH3 
 
H 
 
H 
 
H 
 
H 
 
H 
 
H 
 
H 
 
H 
 
H 
 
H 
 
OCH3 
 
OCH3 
 
OCH3 
 
OCH3 
 
H 
 
H 
 
H 
 
H 
 
OCH3 
 
OCH3 
 
OCH3 
 
OCH3 
 
Cl 
 
Cl 
 
Cl 
 
Cl 
 
H 
 
H 
 
H 
 
H 
 
H 
 
H 
 
H 
 
H 
 
H 
 
H 
 
H 
 
H 
 
H 
 
H 
 
H 
 
H 
 
H 
 
H 
 
H 
 
H 
 
OCH3 
 
OCH3 
 
OCH3 
 
OCH3 
 
141 
 
142 
 
143 
 
144 
 
145 
 
146 
 
147 
 
148 
 
149 
 
150 
 
151 
 
152 
 
153 
 
154 
 
155 
 
156 
 
80 
 
72 
 
10 
 
57 
 
62 
 
54 
 
41 
 
23 
 
55 
 
44 
 
78 
 
77 
 
20 
 
45 
 
56 
 
27 
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R2'
O H
+
R1
R2
R3
CH3
O
OH
NaOH, EtOH
rt., 24 h. OH
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R2'
R1'R1
R2
R3
133-137 65, 105, 107, 138 141-156
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Table 2.6. Synthesis of stilbene fused flavanones (157-171). 
O
OH
142-156
O
O
157-171
NaOAc, EtOH
Reflux
R1
R2
R3
R2'
R1' R1
R2
R3
R1'
R2'
 
Entry Compound R1 R2 R3 R1' R2' Product 
Yield 
(%) 
 
1 
 
2 
 
3 
 
4i 
 
5 
 
6 
 
7 
 
8 
 
9 
 
10 
 
11 
 
12 
 
13 
 
14 
 
15 
 
142 
 
143 
 
144 
 
145 
 
146 
 
147 
 
148 
 
149 
 
150 
 
151 
 
152 
 
153 
 
154 
 
155 
 
156 
 
H 
 
H 
 
H 
 
H 
 
H 
 
H 
 
H 
 
OCH3 
 
OCH3 
 
OCH3 
 
OCH3 
 
H 
 
H 
 
H 
 
H 
 
OCH3 
 
OCH3 
 
OCH3 
 
Cl 
 
Cl 
 
Cl 
 
Cl 
 
H 
 
H 
 
H 
 
H 
 
H 
 
H 
 
H 
 
H 
 
H 
 
H 
 
H 
 
H 
 
H 
 
H 
 
H 
 
H 
 
H 
 
H 
 
H 
 
OCH3 
 
OCH3 
 
OCH3 
 
OCH3 
 
H 
 
CH3 
 
F 
 
H 
 
H 
 
CH3 
 
F 
 
H 
 
H 
 
CH3 
 
F 
 
H 
 
H 
 
CH3 
 
F 
 
CH3 
 
H 
 
H 
 
OCH3 
 
CH3 
 
H 
 
H 
 
OCH3 
 
CH3 
 
H 
 
H 
 
OCH3 
 
CH3 
 
H 
 
H 
 
157 
 
158 
 
159 
 
160 
 
161 
 
162 
 
163 
 
164 
 
165 
 
166 
 
167 
 
168 
 
169 
 
170 
 
171 
 
73 
 
72 
 
76 
 
63 
 
26 
 
76 
 
77 
 
79 
 
64 
 
61 
 
56 
 
68 
 
32 
 
73 
 
49 
 i: Conditions of entry 4: Potassium tert-butoxide / EtOH, r.t. 24 h. 
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Table 2.7. Yields for library of stilbene fused chalcone systems (139,141-156). 
 
Ar2 
 
Ar1 
  
  
 
141  
(80%) 
142  
(72%) 
143  
(10%) 
144  
(57%) 
 
145  
(62%) 
146  
(54%) 
147  
(41%) 
148  
(23%) 
 
149  
(55%) 
150  
(44%) 
151  
(78%) 
152  
(77%) 
 
153  
(20%) 
154  
(45%) 
155  
(56%) 
156  
(27%) 
 
139 
(44%) 
 
O M e M e M e F 
  
M   e   O   
M   e   O   
M e O 
C l 
O M e 
M e O 
O
R2
R1
R3
R1'
R2'
Ar1 Ar2
OH
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Table 2.8. Yields for library of stilbene fused flavanone systems (126,140, 157-171). 
 
Ar2 
 
Ar1 
  
  
 
126  
(44%) 
157  
(73%) 
158  
(72%) 
159  
(76%) 
 
160  
(63%) 
161  
(26%) 
162  
(76%) 
163  
(77%) 
 
164  
(79%) 
165  
(64%) 
166  
(61%) 
167  
(56%) 
 
168  
(68%) 
169  
(32%) 
170 
(73%) 
171  
(49%) 
 
140 
(65%) 
 
 
2.5 Preliminary Cytotoxic Properties of Selected Stilbene Fused 
Chalcone and Flavanone Derivatives 
 
 Ultimate goal of this work is to combine two biologically active compounds in a 
way to produce a new one which has either one type of biological activity with more 
potency or multi-bioactivity. For this purpose synthesis of stilbene fused chalcones and 
M e O 
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O M e 
M e O 
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O M e M e M e F 
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R1'
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flavanones were completed. To show the multi-biological activity of synthesized 
compounds, it is necessary to test synthesized compounds in more than one possible 
target. 
 Two different set of biological activity tests for each library will require large 
amount of time. Instead it might be better to evaluate the efficiency of compounds in 
one type of biological activity as a starting point. 
 For this purpose one stilbene fused flavanone (125) was chosen and tested 
against MCF-7 and PC3 cancer cells. To compare the potency of selected compound, a 
chalcone (110), a flavanone (116) and a stilbene (133) (Figure 2.5) were also prepared 
and tested against same cancer cell lines. As it is discussed earlier it was expected that 
fused product should have more potency than separate flavanone and stilbene. It might 
also have more potency compared the synergetic effect of selected stilbene (133) and 
flavanone (116). Cytotoxic effects of the mixtures of these compounds were also 
evaluated against cancer cell lines at different concentrations. Test results, showing 24 
hours incubation for PC3 and 48 hours incubation of PC3 and MCF-7 were given in 
figures 2.6.-2.8. 
 
Figure 2.5. Selected chalcone (110), flavanone (116), stilbene fused flavanone (126) and 
stilbene (133) structures for cytotoxicity tests on PC3 and MCF-7 cancer 
cell lines. 
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Figure 2.6. Dose dependent cytotoxicities of compounds 110, 133, 116, 116+133 and 
126 on PC3 cancer cell lines after 24 hours incubation. 
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Figure 2.7. Dose dependent cytotoxicities of compounds 110, 133, 116, 116+133 and 
126 on PC3 cancer cell lines after 48 hours incubation. 
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Figure 2.8. Dose dependent cytotoxicities of compounds 110, 133, 116, 116+133 and 
126 on MCF-7 cancer cell lines after 48 hours incubation. 
 
 It is clear from graphs that standard deviations are getting larger when the 
concentrations of the compounds are far below the cytotoxic levels. 
 Response of PC3 cells to the tested compounds after 24 hours shows that the 
most cytotoxic compound is chalcone (110). Stilbene (133) produces no cytotoxicity at 
all tested concentrations. Additionally cytotoxicity levels of flavanone (116), mixture of 
stilbene flavanone and stilbene fused flavanone (126) have similar trend, and levels of 
cytotoxicities were very close to that of chalcone (110). After 48 hours potency of 
chalcone (110) is still the highest. On the other hand fused system clearly works better 
compared to flavanone and stilbene mixture at all tested concentrations. At 1 µM fused 
system (126) is still cytotoxic (85% cell viability), but mixture has no effect at all in 
these concentrations. 
 For MCF-7, stilbene (133) is quite cytotoxic at high concentrations (100-200 
µM) but its fused form (126) only active at concentrations greater than 150 µM. 
Remaining tested compounds have similar trend with PC3. These early results imply 
that activity of stilbene fused flavanones have opposite trend compare to that of stilbene 
only. 
 After this short comparison of biological activity of the fused product with 
simple chalcone, flavanone and stilbene, more stilbene fused chalcones and flavanones 
were tested on PC3 and MCF-7 cell lines. Structures of tested compounds are given in 
figure 2.9 and 2.10. 
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 Among the tested samples, stilbene fused chalcones 139 and 156 and stilbene 
fused flavanones 140, 158, 160, 167 and 171 have no cytotoxic effects on MCF-7 and 
PC3 cancer cell lines at tested concentrations below 50 µM. 
 On the other hand chalcones 145 and 141, 143, 149 and 152 are quite effective 
on PC3 at concentrations higher than 10 µM and on MCF-7 at concentrations higher 
than 25 µM. Especially chalcone 143 is highly cytotoxic at submicromolar 
concentrations for both cancer cell lines. 
 Although it is too early to talk about the complete structure activity relationship 
for the libraries, these preliminary cytotoxicity test results imply that stilbene fused 
chalcones are much more cytotoxic compared to their flavanone isomers. Activities of 
chalcones depend on substituents originated from styrenes and acetophenones. 
 
Figure 2.9. Structures of selected stilbene fused chalcones (139,145,152 and 156) and 
stilbene fused flavanones (140,167 and 171). 
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Figure 2.10. Structures of selected stilbene fused chalcones (141,143 and 149) and 
stilbene fused flavanones (158,160 and 164). 
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Figure 2.11. Dose dependent cytotoxicities of compounds 141, 143, 145, 149, 152 and 
164 on MCF-7 cancer cell lines after 48 hours incubation. 
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Figure 2.12. Dose dependent cytotoxicities of compounds 141, 143, 145, 149 and 152 
on PC3 cancer cell lines after 48 hours incubation 
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CHAPTER 3  
 
EXPERIMENTAL   
 
3.1. Chemistry Part 
 
3.1.1. General Methods 
 
 Reagents were commercial grade and were used as supplied. Reactions were 
monitored by thin layer chromatography by using Merck TLC plates (Silica gel 60 
F254). Chromatographic separations and isolations of compounds were performed by 
column chromatography. 70-230 mesh silica gel was used for column chromatography. 
Solvents were also commercial grade and were used as supplied. 1H NMR and 13C 
NMR data were recorded on Varian 400-MR (400 MHz) spectrometer. Chemical shifts 
for 1H-NMR and 13C-NMR are reported in δ (ppm). CDCl3 peaks were used as 
reference in 1H-NMR (7.26 ppm), and 13C-NMR (77.36 ppm) respectively. 
 
3.1.2. Synthesis of Chalcone Derivatives (110-115) 
 
3.1.2.1. (E)-3-(3-bromophenyl)-1-(2-hydroxy-5-methoxyphenyl)prop-2-
en-1-one (110)  
 
 A mixture of 950.0 mg (5.72 mmol) of 2-hydroxy-5-methoxyacetophenone and 
1.05 g (5.68 mmol) of 3-bromobenzaldehyde in anhydrous ethanol was prepared, and 
stirred for 5 minutes. Then 700.0 mg (18.00 mmol) of NaOH (3.15 eq.) was added to 
this solution. The reaction mixture was stirred 18 h. at room temperature. Then 10% 
HCl was added to neutralize this solution. Resulting solution was extracted with ethyl 
acetate (2x40 ml) and combined organic phase was washed with brine solution (2x25 
ml). Resulting organic phase was dried over MgSO4. After the removal of the solvent 
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under vacuum, crude product was purified by column chromatography on silica gel 
(1:12 EtOAc/Hexanes) to furnish 909.4 mg of (E)-3-(3-bromophenyl)-1-(2-hydroxy-5-
methoxyphenyl)prop-2-en-1-one as orange solid with 46% yield. Rf = 0.50 (ethyl 
acetate/hexanes, 1:4); 1H NMR (400 MHz, CDCl3) δ = 12.26 (s, 1H), 7.87–7.78 (m, 
2H), 7.62–7.52 (m, 3H), 7.36–7.27 (m, 2H), 7.16 (dd, J = 9.1, 3.0 Hz, 1H), 6.99 (d, J = 
9.1 Hz, 1H), 3.85 (s, 3H); 13C NMR (100 MHz, CDCl3) δ = 193.35, 158.37, 152.14, 
144.07, 137.04, 133.98, 131.32, 130.90, 127.84, 124.52, 123.53, 121.85, 119.85, 
119.81, 113.28, 56.57. 
 
3.1.2.2. (E)-3-(3-bromophenyl)-1-(5-chloro-2-hydroxyphenyl)prop-2-
en-1-one (111) 
 
 A mixture of 1.05 g (6.18 mmol) of 2-hydroxy-5-chloroacetophenone and 1.1 g 
(5.95 mmol) of 3-bromobenzaldehyde in anhydrous ethanol was prepared, and stirred 
for 5 minutes. Then 1.1 g (27.5 mmol) of NaOH (4.62 eq.) was added to this solution. 
The reaction mixture was stirred 24 h. at room temperature. Then 10% HCl was added 
to neutralize this solution. Resulting solution was extracted with ethyl acetate (3x30 ml) 
and combined organic phase was washed with brine solution (2x25 ml). Resulting 
organic phase was dried over MgSO4. After the removal of the solvent under vacuum, 
crude product was purified by column chromatography on silica gel (1:12 
EtOAc/Hexanes) to furnish 1.9 mg of (E)-3-(3-bromophenyl)-1-(5-chloro-2-
hydroxyphenyl)prop-2-en-1-one as orange solid with 93% yield. Rf = 0.40 (ethyl 
acetate/hexanes, 1:4); 1H NMR (400 MHz, CDCl3) δ = 12.61 (s, 1H), 7.86–7.79 (m, 
3H), 7.60–7.50 (m, 3H), 7.47–7.42 (m, 1H), 7.32 (dd, J = 7.9, 7.9 Hz, 1H), 7.01–6.96 
(m, 1H); 13C NMR (100 MHz, CDCl3) δ = 192.75, 162.42, 144.92, 136.77, 136.68, 
134.25, 131.50, 130.92, 129.12, 127.91, 123.98, 123.57, 121.04, 120.75, 120.64. 
 
3.1.2.3.(E)-3-(3-bromophenyl)-1-(2-hydroxy-4,6-dimethoxyphenyl) 
prop-2-en-1-one (112) 
 
 A mixture of 470.0 mg (2.40 mmol) of 2-hydroxy-4,6-dimethoxyacetophenone 
and 278.0 mg (2.43 mmol) of 3-bromobenzaldehyde in anhydrous ethanol was 
prepared, and stirred for 5 minutes. Then 600.0 mg (15.00 mmol) of NaOH (6.25 eq.) 
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was added to this solution. The reaction mixture was stirred 24 h. at room temperature. 
Then 10% HCl was added to neutralize this solution. Resulting solution was extracted 
with ethyl acetate (2x30 ml) and combined organic phase was washed with brine 
solution (2x25 ml). Resulting organic phase was dried over MgSO4. After the removal 
of the solvent under vacuum, crude product was purified by column chromatography on 
silica gel (1:10 EtOAc/Hexanes) to furnish 333.0 mg of (E)-3-(3-bromophenyl)-1-(2-
hydroxy-4,6-dimethoxyphenyl)prop-2-en-1-one as orange solid with 92% yield. Rf = 
0.25 (ethyl acetate/hexanes, 1:4); 1H NMR (400 MHz, CDCl3) δ = 7.84 (d, J = 15.6 Hz, 
1H), 7.72 (dd, J = 1.8 Hz, 1H), 7.65 (d, J = 15.6 Hz, 1H), 7.53–7.46 (m, 2H), 7.27 (dd, J 
= 7.9, 7.9 Hz, 1H), 6.11 (d, J = 2.4 Hz, 1H), 5.96 (d, J = 2.4 Hz, 1H), 3.92 (s, 3H), 3.84 
(s, 3H); 13C NMR (100 MHz, CDCl3) δ = 192.49, 168.77, 166.76, 162.79, 140.60, 
138.07, 133.01, 131.17, 130.66, 129.21, 127.28, 123.30, 106.57, 94.12, 91.63, 56.24, 
55.92. 
 
3.1.2.4. (E)-3-(3-bromophenyl)-1-(2-hydroxy-6-methoxyphenyl)prop-2-
en-1-one (113) 
 
 A mixture of 250.0 mg (1.51 mmol) of 2-hydroxy-6-methoxyacetophenone and 
278.0 mg (1.50 mmol) of 3-bromobenzaldehyde in anhydrous ethanol was prepared, 
and stirred for 5 minutes. Then 200.0 mg (5.00 mmol) of NaOH (3.33 eq.) was added to 
this solution. The reaction mixture was stirred 24 h. at room temperature. Then 10% 
HCl was added to neutralize this solution. Resulting solution was extracted with ethyl 
acetate (2x30 ml) and combined organic phase was washed with brine solution (2x25 
ml). Resulting organic phase was dried over MgSO4. After the removal of the solvent 
under vacuum, crude product was purified by column chromatography on silica gel 
(1:12 EtOAc/Hexanes) to furnish 454.0 mg of (E)-3-(3-bromophenyl)-1-(2-hydroxy-6-
methoxyphenyl)prop-2-en-1-one as orange solid with 91% yield. Rf = 0.40 (ethyl 
acetate/hexanes, 1:4); 1H NMR (400 MHz, CDCl3) δ = 12.95 (s, 1H), 7.73 (d, J = 15.6 
Hz, 1H), 7.65 (dd, J = 1.8, 1.8 Hz, 1H), 7.60 (d, J = 15.6 Hz, 1H), 7.45–7.40 (m, 2H), 
7.32–7.25 (m, 1H), 7.22–7.16 (m, 1H), 6.53 (dd, J = 8.4, 1.0 Hz, 1H), 6.35 (dd, J = 8.3, 
0.8 Hz., 1H), 3.87 (s, 3H); 13C NMR (100 MHz, CDCl3) δ = 194.44, 165.21, 161.29, 
141.20, 137.80, 136.52, 133.27, 131.27, 130.72, 129.23, 127.40, 123.34, 112.17, 
111.30, 101.88, 56.34. 
 
 
48 
3.1.2.5. (E)-3-(3-bromophenyl)-1-(2-4-dihydroxy-3-methylphenyl)prop-
2-en-1-one (114) 
 
 A mixture of 997.0 mg (6.00 mmol) of 2,4-dihydroxy-3-methylacetophenone 
and 1.1 g (5.95 mmol) of 3-bromobenzaldehyde in anhydrous ethanol was prepared, and 
stirred for 5 minutes. Then 1.1 g (27.5 mmol) of NaOH (4.62 eq.) was added to this 
solution. The reaction mixture was stirred 24 h. at room temperature. Then 10% HCl 
was added to neutralize this solution. Resulting solution was extracted with ethyl acetate 
(3x40 ml) and combined organic phase was washed with brine solution (2x25 ml). 
Resulting organic phase was dried over MgSO4. After the removal of the solvent under 
vacuum, crude product was purified by column chromatography on silica gel (1:12 
EtOAc/Hexanes) to furnish 1.8 g of (E)-3-(3-bromophenyl)-1-(2,4-dihydroxy-3-
methylphenyl)prop-2-en-1-one as orange solid with 90% yield. Rf = 0.20 (ethyl 
acetate/hexanes, 1:4); formation of the product was observed from NMR spectrum of 
crude product, and this crude product was used in next step (Formation of product 120).  
 
3.1.2.6.(E)-3-(3-bromophenyl)-1-(2-hydroxy-5-methyl-3-nitrophenyl) 
prop-2-en-1-one (115) 
 
 A mixture of 390.0 mg (2.00 mmol) of 2-hydroxy-5-methyl-3-nitroacetophenone 
and 370.0 mg (2.00 mmol) of 3-bromobenzaldehyde was stirred together in the presence 
of 30% L-Proline in DMF (0.02 M) at 80 oC for 18 hours. Then solution was extracted 
with ethyl acetate (2x30 ml) and combined organic phase was washed with brine 
solution (2x20 ml). Resulting organic phase was dried over MgSO4. After the removal 
of the solvent under vacuum, crude product was purified by column chromatography on 
silica gel (1:10 EtOAc/Hexanes) to furnish 41.0 mg of (E)-3-(3-bromophenyl)-1-(2-
hydroxy-5-methyl-3-nitrophenyl)prop-2-en-1-one as orange solid with 15% yield. Rf = 
0.25 (ethyl acetate/hexanes, 1:4); 1H NMR (400 MHz, CDCl3) δ = 8.09–8.05 (m, 1H), 
7.94 (dd, J = 2.3, 0.6 Hz, 1H), 7.84–7.76 (m, 2H), 7.60–7.49 (m, 4H), 7.32 (dd, J = 7.9, 
7.9 Hz, 1H). 
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3.1.3. Synthesis of Flavanone Derivatives (116,117,119) 
 
3.1.3.1. 2-(3-bromophenyl)-6-methoxychroman-4-one (116) 
 
 A solution of 1.60 g (4.80 mmol) of (E)-3-(3-bromophenyl)-1-(2-hydroxy-5-
methoxyphenyl)prop-2-en-1-one in 125.0 ml of glacial acetic acid was heated at reflux 
for 72 h. At the end of this period, reaction mixture was cooled to room temperature, 
and solution was poured into 40.0 ml of water and extracted with ethyl acetate 
(3x40ml). Combined organic phase was washed with brine (2x50 ml) and dried over 
MgSO4. After removal of the solvent under vacuum, crude product was purified by 
column chromatography on silica gel (1:12 EtOAc/Hexanes) to furnish 1.30 g of 2-(3-
bromophenyl)-6-methoxychroman-4-one as yellow solid with 79% yield. Rf = 0.16 
(ethyl acetate/hexanes, 1:6); 1H NMR (400 MHz, CDCl3) δ = 7.67 (dd, J = 1.6, 1.6 Hz, 
1H), 7.53–7.48 (m, 1H), 7.40–7.25 (m, 3H), 7.13 (dd, J = 9.0, 3.1 Hz, 1H), 7.00 (d, J = 
9.0 Hz, 1H), 5.40 (dd, J = 13.2, 3.1 Hz, 1H), 3.82 (s, 3H), 3.00 (dd, J = 16.9, 13.2 Hz, 
1H), 2.87 (dd, J = 16.9, 3.1 Hz, 1H); 13C NMR (100 MHz, CDCl3) δ = 191.75, 156.26, 
154.76, 141.48, 132.09, 130.72, 129.58, 125.80, 124.95, 123.27, 121.10, 119.73, 
107.79, 79.14, 56.17, 44.91. 
  
3.1.3.2. 2-(3-bromophenyl)-6-chlorochroman-4-one (117) 
 
 A solution of  1.85 g (5.49 mmol) of (E)-3-(3-bromophenyl)-1-(5-chloro-2-
hydroxyphenyl)prop-2-en-1-one in 150.0 ml of glacial acetic acid was heated at reflux 
during 72 hours. At the end of this period, reaction mixture was cooled to room 
temperature, and solution was poured into 40 ml of water and extracted with ethyl 
acetate (3x40ml). Combined organic phase was washed with brine (2x50 ml) and dried 
over MgSO4. After removal of the solvent under vacuum, crude product was purified  
by column chromatography on silica gel (1:10 EtOAc/Hexanes)  to furnish 1.30 g of 2-
(3-bromophenyl)-6-chlorochroman-4-one as white solid with 90% yield. Rf = 0.18 
(ethyl acetate/hexanes, 1:8); 1H NMR (400 MHz, CDCl3) δ = 7.93–7.82 (m, 1H), 7.71–
7.62 (m, 1H), 7.58–7.22 (m, 4H), 7.10–6.97 (m, 1H), 5.44 (dd, J = 12.8, 2.8 Hz, 1H), 
3.14–2.79 (m, 2H); 13C NMR (100 MHz, CDCl3) δ = 190.11, 159.60, 140.52, 136.10, 
131.96, 130.45, 129.21, 127.44, 126.41, 124.60, 122.98, 121.64, 119.82, 78.87, 44.23. 
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3.1.3.3. 2-(3-bromophenyl)-5-methoxychroman-4-one (119) 
 
 A solution of  533.0 mg (1.60 mmol) of (E)-3-(3-bromophenyl)-1-(2-hydroxy-6-
methoxyphenyl)prop-2-en-1-one in ethanol was prepared. 1.3 g of anhydrous sodium 
acetate was added to this solution. Final solution was heated at reflux for 24 h. At the 
end of this period, reaction mixture was cooled to room temperature, and solution was 
poured into 40 ml of water and extracted with ethyl acetate (3x40ml). Combined 
organic phase was washed with brine (2x50 ml) and dried over MgSO4. After removal 
of the solvent under vacuum, crude product was purified by column chromatography on 
silica gel (1:12 EtOAc/Hexanes) to furnish 240.0 mg of 2-(3-bromophenyl)-5-
methoxychroman-4-one as yellow solid with 45% yield. Rf = 0.16 (ethyl 
acetate/hexanes, 1:6); 1H NMR (400 MHz, CDCl3) δ = 7.66 (s, 1H), 7.51 (d, J = 7.8 Hz, 
1H), 7.47–7.35 (m, 2H), 7.34–7.25 (m, 1H), 6.68 (d, J = 8.3 Hz, 1H), 6.58 (d, J = 8.4 
Hz, 1H), 5.41 (d, J = 13.1 Hz, 1H), 3.94 (s, 3H), 3.08–2.95 (m, 1H), 2.86 (d, J = 16.4 
Hz, 1H). 
 
3.1.4. Synthesis of Stilbene Derivatives (133-136) 
 
3.1.4.1. Preparation of Catalyst for Heck Reaction 
 
 In a 100 ml flask, 6.3 mg (2.8x10-4 mmol) of Pd(OAc)2 was dissolved in 100 ml 
of NMP and 2.8x10-3 M stock solution was prepared. This solution was stored in cold 
medium.  
 
3.1.4.2. (E)-3-(4-methoxystyryl)benzaldehyde (133) 
 
 A double neck round bottom flask was filled with 451.0 mg (5.50 mmol) of 
NaOAc, 925.1 mg of (5.00 mmol, 583.0 µl) 3-bromobenzaldehyde and 10 ml NMP. 
10.7 ml of stock solution of catalyst (containing 0.06 mol% Pd(OAc)2 compared to 3-
bromobenzaldehyde) was added to reaction vessel by a syringe under nitrogen 
atmosphere. The reaction mixture was stirred and heated to 120 oC, and then 670.9 mg 
(5.00 mmol, 672.0 µl) of 4-methoxystyrene was added to reaction mixture. Then 
reaction mixture was heated to 135 oC, and stirred at this temperature for 18 hours. The 
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resulting mixture was cooled to room temperature and poured into the 50.0 ml of water. 
Then mixture extracted with ethyl acetate (3x40 ml). The combined organic phase 
washed with brine (3x40 ml) and dried over MgSO4. After removal of solvent under 
vacuum, purification of the crude product was performed by column chromatography 
on silica gel (1:10 EtOAc/Hexanes) gave 1.1 g of (E)-3-(4-
methoxylstyryl)benzaldehyde as white powder with 93% yield. Rf = 0.55 (ethyl 
acetate/hexanes, 1:6); 1H NMR (400 MHz, CDCl3) δ = 10.00 (d, J = 5.0 Hz, 1H), 7.95 
(s, 1H), 7.75–7.63 (m, 2H), 7.52–7.39 (m, 3H), 7.12 (d, J = 16.3 Hz, 1H), 7.02–6.85 (m, 
3H), 3.80 (s, 3H); 13C NMR (100 MHz, CDCl3) δ = 192.53, 159.85, 138.80, 136.94, 
132.19, 130.14, 129.63, 129.45, 128.53, 128.16, 127.11, 125.04, 114.40, 55.45. 
 
3.1.4.3. (E)-3-(4-methylstyryl)benzaldehyde (134) 
 
 A double neck round bottom flask was filled with 451.0 mg (5.50 mmol) of 
NaOAc, 925.1 mg of (5.00 mmol, 583.0 µl) 3-bromobenzaldehyde and 10 ml NMP. 
10.7 ml of stock solution of catalyst (containing 0.06 mol% Pd(OAc)2 compared to 3-
bromobenzaldehyde) was added to reaction vessel by a syringe under nitrogen 
atmosphere. The reaction mixture was stirred and heated to 120 oC, and then 590.9 mg 
(5.00 mmol, 659.0 µl) of 4-methylstyrene was added to reaction mixture. Then reaction 
mixture was heated to 135 oC, and stirred at this temperature for 18 hours. The resulting 
mixture was cooled to room temperature and poured into the 50.0 ml of water. Then 
mixture extracted with ethyl acetate (3x40 ml). The combined organic phase washed 
with brine (3x40 ml) and dried over MgSO4. After removal of solvent under vacuum, 
purification of the crude product was performed by column chromatography on silica 
gel (1:10 EtOAc/Hexanes) gave 889.0 mg of (E)-3-(4-methylstyryl)benzaldehyde as 
white powder with 80% yield. Rf = 0.60 (ethyl acetate/hexanes, 1:6); 1H NMR (400 
MHz, CDCl3) δ = 10.04 (s, 1H), 8.00 (dd, J = 1.6, 1.6 Hz, 1H), 7.78–7.70 (m, 2H), 
7.56–7.47 (m, 1H), 7.44 (d, J = 8.1 Hz, 2H), 7.29–7.02 (m, 4H), 2.38 (s, 3H); 13C NMR 
(100 MHz, CDCl3) δ = 192.62, 138.80, 138.41, 137.06, 134.20, 132.46, 130.69, 129.78, 
129.58, 128.86, 127.39, 126.90, 126.33, 21.58. 
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3.1.4.4. (E)-3-(3-methylstyryl)benzaldehyde (135) 
 
 A double neck round bottom flask was filled with 451.0 mg (5.50 mmol) of 
NaOAc, 925.1 mg of (5.00 mmol, 583.0 µl) 3-bromobenzaldehyde and 10 ml NMP. 
10.7 ml of stock solution of catalyst (containing 0.06 mol% Pd(OAc)2 compared to 3-
bromobenzaldehyde) was added to reaction vessel by a syringe under nitrogen 
atmosphere. The reaction mixture was stirred and heated to 120 oC, and then 591.0 mg 
(5.00 mmol, 664.0 µl) of 3-methylstyrene was added to reaction mixture. Then reaction 
mixture was heated to 135 oC, and stirred at this temperature for 18 hours. The resulting 
mixture was cooled to room temperature and poured into the 50.0 ml of water. Then 
mixture extracted with ethyl acetate (3x40 ml). The combined organic phase washed 
with brine (2x40 ml) and dried over MgSO4. After removal of solvent under vacuum, 
purification of the crude product was performed by column chromatography on silica 
gel (1:10 EtOAc/Hexanes) gave 1.0 g of (E)-3-(3-methylstyryl)benzaldehyde as white 
powder with 90% yield. Rf = 0.60 (ethyl acetate/hexanes, 1:6); 1H NMR (400 MHz, 
CDCl3) δ = 10.05 (s, 1H), 8.02 (s, 1H), 7.79–7.71 (m, 2H), 7.56–7.48 (m, 1H), 7.35 (d, 
J = 8.2 Hz, 2H), 7.28 (dd, J = 11.6, 4.2 Hz, 1H), 7.23–7.08 (m, 3H), 2.40 (s, 3H); 13C 
NMR (100 MHz, CDCl3) δ = 192.58, 138.70, 138.62, 137.08, 136.92, 132.54, 130.88, 
129.61, 129.27, 128.99, 128.96, 127.67, 127.47, 127.13, 124.18, 21.73. 
 
3.1.4.5. (E)-3-(3-fluorostyryl)benzaldehyde (136) 
 
 A double neck round bottom flask was filled with 451.0 mg (5.50 mmol) of 
NaOAc, 925.1 mg of (5.00 mmol, 583.0 µl) 3-bromobenzaldehyde and 10 ml NMP. 
10.7 ml of stock solution of catalyst (containing 0.06 mol% Pd(OAc)2 compared to 3-
bromobenzaldehyde) was added to reaction vessel by a syringe under nitrogen 
atmosphere. The reaction mixture was stirred and heated to 120 oC, and then 610.7 mg 
(5.00 mmol, 596.0 µl) of 3-fluorostyrene was added to reaction mixture. Then reaction 
mixture was heated to 135 oC, and stirred at this temperature for 20 hours. The resulting 
mixture was cooled to room temperature and poured into the 50.0 ml of water. Then 
mixture extracted with ethyl acetate (3x40 ml). The combined organic phase washed 
with brine (2x40 ml) and dried over MgSO4. After removal of solvent under vacuum, 
purification of the crude product was performed by column chromatography on silica 
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gel (1:10 EtOAc/Hexanes) gave 850.0 mg of (E)-3-(3-fluorostyryl)benzaldehyde as 
white powder with 75% yield. Rf = 0.50 (ethyl acetate/hexanes, 1:6); 1H NMR (400 
MHz, CDCl3) δ = 10.03 (s, 1H), 7.99 (dd, J = 1.7, 1.7 Hz, 1H), 7.79–7.74 (m, 1H), 7.71 
(ddd, J = 5.0, 3.2, 1.8 Hz, 1H), 7.51 (dd, J = 7.6, 7.6 Hz, 1H), 7.36–7.24 (m, 2H), 7.23–
7.17 (m, 1H), 7.11 (d, J = 2.5 Hz, 2H), 6.98 (tdd, J = 8.4, 2.6, 1.1 Hz, 1H); 13C NMR 
(100 MHz, CDCl3) δ = 192.41, 164.62, 162.17, 139.33, 139.26, 138.05, 137.08, 132.65, 
130.53, 130.44, 129.66, 129.47, 129.44, 128.63, 127.48, 122.95, 122.92, 115.27, 
115.06, 113.30, 113.08. 
 
3.1.5. Synthesis of Stilbene Fused Chalcone Derivatives (139,141-156) 
 
3.1.5.1. (E)-1-(2-hydroxy-5-methoxyphenyl)-3-(3-((E)-4-methoxystyryl) 
phenyl)prop-2-en-1-one (141) 
 
 A mixture of 238.0 mg (1.00 mmol) of (E)-3-(4-methoxystyryl)benzaldehyde 
and 166.0 mg (1.00 mmol) of 2-hydroxy-5-methoxyacetophenone in anhydrous ethanol 
was stirred for 5 min. Then 400 mg (10.0 mmol) of NaOH (10.0 eq.) was added to this 
solution. The reaction mixture was stirred for 24 h at room temperature. Resulting 
solution was neutralized by 10% HCl. Obtained mixture was extracted with 2x30 ml 
ethyl acetate. The combined organic phase was washed with brine solution (2x25 ml) 
and dried over MgSO4. After the removal of the solvent under vacuum, the crude 
product was purified by column chromatography on silica gel (1:10 EtOAc/Hexanes) to 
give 309.0 mg of (E)-1-(2-hydroxy-5-methoxyphenyl)-3-(3-((E)-4-methoxystyryl) 
phenyl)prop-2-en-1-one as orange solid with 80% yield. Rf = 0.29 (ethyl 
acetate/hexanes, 1:6); 1H NMR (400 MHz, CDCl3) δ = 12.39 (s, 1H), 7.93 (d, J = 15.5 
Hz, 1H), 7.72 (s, 1H), 7.62 (d, J = 15.5 Hz, 1H), 7.59–7.45 (m, 4H), 7.44–7.37 (m, 2H), 
7.19–7.09 (m, 2H), 7.04–6.88 (m, 4H), 3.85 (s, 3H), 3.84 (s, 3H); 13C NMR (100 MHz, 
CDCl3) δ = 193.67, 159.90, 158.26, 152.03, 145.95, 138.88, 135.26, 130.00, 129.77, 
129.64, 128.85, 128.23, 127.57, 126.96, 125.82, 124.11, 120.61, 119.99, 119.68, 
114.53, 113.45, 56.53, 55.68. 
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3.1.5.2. (E)-1-(2-hydroxy-5-methoxyphenyl)-3-(3-((E)-4-methystyryl) 
phenyl)prop-2-en-1-one (142) 
 
 A mixture of 222.0 mg (1.0 mmol) of (E)-3-(4-methylstyryl)benzaldehyde and 
166.0 mg (1.0 mmol) of 2-hydroxy-5-methoxyacetophenone in anhydrous ethanol was 
stirred for 5 min. Then 400 mg (10.0 mmol) of NaOH (10.0 eq.) was added to this 
solution. The reaction mixture was stirred for 24 h at room temperature. Resulting 
solution was neutralized by 10% HCl. Obtained mixture was extracted with 3x30 ml 
ethyl acetate. The combined organic phase was washed with brine solution (2x25 ml) 
and dried over MgSO4. After the removal of the solvent under vacuum, the crude 
product was purified by column chromatography on silica gel (1:10 EtOAc/Hexanes) to 
give 267.0 mg of (E)-1-(2-hydroxy-5-methoxyphenyl)-3-(3-((E)-4-methylstyryl) 
phenyl)prop-2-en-1-one as orange solid with 72% yield. Rf = 0.43 (ethyl 
acetate/hexanes, 1:6); 1H NMR (400 MHz, CDCl3) δ = 12.43 (d, J = 1.4 Hz, 1H), 7.92 
(d, J = 15.5 Hz, 1H), 7.71 (s, 1H), 7.64–7.50 (m, 3H), 7.47–7.35 (m, 4H), 7.22–7.03 (m, 
5H), 6.99 (d, J = 9.1 Hz, 1H), 3.85 (s, 3H), 2.38 (s, 3H); 13C NMR (100 MHz, CDCl3) δ 
= 193.61, 158.24, 152.01, 145.83, 138.69, 138.28, 135.24, 134.41, 130.13, 129.79, 
129.61, 128.93, 127.73, 127.09, 126.91, 126.88, 124.07, 120.58, 119.96, 119.64, 
113.43, 56.48, 21.61. 
 
3.1.5.3. (E)-1-(2-hydroxy-5-methoxyphenyl)-3-(3-((E)-3-methylstyryl) 
phenyl)prop-2-en-1-one (143) 
 
 A mixture of 222.0 mg (1.0 mmol) of (E)-3-(3-methylstyryl)benzaldehyde and 
166.0 mg (1.0 mmol) of 2-hydroxy-5-methoxyacetophenone in anhydrous ethanol was 
stirred for 5 min. Then 400 mg (10.0 mmol) of NaOH (10.0 eq.) was added to this 
solution. The reaction mixture was stirred for 24 h at room temperature. Resulting 
solution was neutralized by 10% HCl. Obtained mixture was extracted with 3x30 ml 
ethyl acetate. The combined organic phase was washed with brine solution (2x25 ml) 
and dried over MgSO4. After the removal of the solvent under vacuum, the crude 
product was purified by column chromatography on silica gel (1:10 EtOAc/Hexanes) to 
give 37.0 mg of (E)-1-(2-hydroxy-5-methoxyphenyl)-3-(3-((E)-3-methylstyryl) 
phenyl)prop-2-en-1-one as orange solid with 10% yield. Rf = 0.43 (ethyl 
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acetate/hexanes, 1:6); 1H NMR (400 MHz, CDCl3) δ = 12.37 (s, 1H), 7.94 (d, J = 15.4 
Hz, 1H), 7.75 (s, 1H), 7.66–7.53 (m, 3H), 7.47–7.33 (m, 4H), 7.29 (d, J = 7.5 Hz, 1H), 
7.20–7.08 (m, 4H), 7.00 (d, J = 9.1 Hz, 1H), 3.86 (s, 3H), 2.40 (s, 3H); 13C NMR (100 
MHz, CDCl3) δ = 193.67, 158.28, 152.06, 145.85, 138.68, 138.66, 137.16, 135.33, 
130.38, 129.69, 129.19, 129.05, 129.00, 127.93, 127.76, 127.67, 127.16, 124.19, 
124.11, 120.72, 120.01, 119.69, 113.52, 56.56, 21.79. 
 
3.1.5.4. (E)-1-(2-hydroxy-5-methoxyphenyl)-3-(3-((E)-3-fluorostyryl) 
phenyl)prop-2-en-1-one (144) 
 
 A mixture of 226.0 mg (1.0 mmol) of (E)-3-(4-fluorostyryl)benzaldehyde and 
166.0 mg (1.0 mmol) of 2-hydroxy-5-methoxyacetophenone in anhydrous ethanol was 
stirred for 5 min. Then 400 mg (10.0 mmol) of NaOH (10.0 eq.) was added to this 
solution. The reaction mixture was stirred for 24 h at room temperature. Resulting 
solution was neutralized by 10% HCl. Obtained mixture was extracted with 3x30 ml 
ethyl acetate. The combined organic phase was washed with brine solution (2x25 ml) 
and dried over MgSO4. After the removal of the solvent under vacuum, the crude 
product was purified by column chromatography on silica gel (1:10 EtOAc/Hexanes) to 
give 214.0 mg of (E)-1-(2-hydroxy-5-methoxyphenyl)-3-(3-((E)-4-fluorostyryl) 
phenyl)prop-2-en-1-one as orange solid with 57% yield. Rf = 0.39 (ethyl 
acetate/hexanes, 1:6); 1H NMR (400 MHz, CDCl3) δ = 12.33 (d, J = 1.8 Hz, 1H), 7.93 
(d, J = 15.5 Hz, 1H), 7.74 (dd, J = 1.6, 1.6 Hz, 1H), 7.65–7.55 (m, 3H), 7.44 (dd, J = 7.7 
Hz, 1H), 7.39 (d, J = 3.0 Hz, 1H), 7.37–7.22 (m, 3H), 7.16 (dd, J = 9.1, 3.0 Hz, 1H), 
7.13 (s, 2H), 7.03–6.95 (m, 2H), 3.86 (s, 3H); 13C NMR (100 MHz, CDCl3) δ = 193.62, 
164.78, 162.34, 158.32, 152.11, 145.61, 139.68, 139.60, 138.11, 135.47, 130.58, 
130.49, 129.76, 129.36, 129.15, 129.09, 129.06, 128.29, 127.32, 124.14, 122.98, 
122.95, 120.94, 120.02, 119.71, 115.23, 115.01, 113.60, 113.38, 113.16, 56.57. 
 
3.1.5.5. (E)-1-(2-hydroxy-5-chlorophenyl)-3-(3-((E)-4-methoxystyryl) 
phenyl)prop-2-en-1-one (145) 
 
 A mixture of 80.0 mg (0.34 mmol) of (E)-3-(4-methoxylstyryl)benzaldehyde 
and 58.0 mg (0.34 mmol) of 5-chloro-2-hydroxyacetophenone in anhydrous ethanol was 
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stirred for 5 min. Then 40 mg (1.0 mmol) of NaOH (3.0 eq.) was added to this solution. 
The reaction mixture was stirred for 24 h at room temperature. Resulting solution was 
neutralized by 10% HCl. Obtained mixture was extracted with 3x30 ml ethyl acetate. 
The combined organic phase was washed with brine solution (2x25 ml) and dried over 
MgSO4. After the removal of the solvent under vacuum, the crude product was purified 
by column chromatography on silica gel (1:10 EtOAc/Hexanes) to give 80.0 mg of (E)-
1-(2-hydroxy-5-chlorophenyl)-3-(3-((E)-4-methoxylstyryl) phenyl)prop-2-en-1-one as 
yellow solid with 62% yield. Rf = 0.48 (ethyl acetate/hexanes, 1:6); 1H NMR (400 
MHz, CDCl3) δ = 12.61 (s, 1H), 7.81 (d, J = 15.4 Hz, 1H), 7.74 (s, 1H), 7.58 (s, 1H), 
7.47–7.37 (m, 3H), 7.37–7.24 (m, 4H), 7.03–6.94 (m, 1H), 6.90–6.82 (m, 2H), 6.78 (d, 
J = 7.8 Hz, 2H), 3.70 (s, 3H); 13C NMR (100 MHz, CDCl3) δ = 193.07, 162.41, 159.92, 
146.84, 138.94, 136.52, 134.98, 129.97, 129.85, 129.70, 129.68, 129.15, 128.25, 
127.77, 127.05, 125.72, 123.85, 120.95, 120.91, 120.57, 119.83, 119.82, 114.53, 55.66. 
 
3.1.5.6. (E)-1-(2-hydroxy-5-chlorophenyl)-3-(3-((E)-4-methylstyryl) 
phenyl)prop-2-en-1-one (146) 
 
 A mixture of 175.0 mg (0.8 mmol) of (E)-3-(4-methylstyryl)benzaldehyde and 
135.0 mg (0.8 mmol) of 5-chloro-2-hydroxyacetophenone in anhydrous ethanol was 
stirred for 5 min. Then 320 mg (8.0 mmol) of NaOH (10.0 eq.) was added to this 
solution. The reaction mixture was stirred for 24 h at room temperature. Resulting 
solution was neutralized by 10% HCl. Obtained mixture was extracted with 3x30 ml 
ethyl acetate. The combined organic phase was washed with brine solution (2x25 ml) 
and dried over MgSO4. After the removal of the solvent under vacuum, the crude 
product was purified by column chromatography on silica gel (1:10 EtOAc/Hexanes) to 
give 160.0 mg of (E)-1-(2-hydroxy-5-chlorophenyl)-3-(3-((E)-4-methylstyryl) 
phenyl)prop-2-en-1-one as yellow solid with 54% yield. Rf = 0.65 (ethyl 
acetate/hexanes, 1:6); 1H NMR (400 MHz, CDCl3) δ = 12.74 (s, 1H), 7.97 (d, J = 15.4 
Hz, 1H), 7.90 (d, J = 2.5 Hz, 1H), 7.76 (s, 1H), 7.64–7.53 (m, 3H), 7.48–7.40 (m, 4H), 
7.23–7.06 (m, 4H), 7.00 (d, J = 8.9 Hz, 1H), 2.38 (s, 3H); 13C NMR (100 MHz, CDCl3) 
δ = 193.10, 162.42, 146.84, 138.82, 138.37, 136.57, 135.01, 134.41, 130.29, 129.83, 
129.73, 129.27, 129.18, 128.00, 127.20, 126.92, 126.88, 123.88, 120.93, 120.60, 
119.92, 21.66. 
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3.1.5.7. (E)-1-(2-hydroxy-5-chlorophenyl)-3-(3-((E)-3-methylstyryl) 
phenyl)prop-2-en-1-one (147) 
 
 A mixture of 222.0 mg (1.0 mmol) of (E)-3-(3-methylstyryl)benzaldehyde and 
170.0 mg (1.0 mmol) of 5-chloro-2-hydroxyoxyacetophenone in anhydrous ethanol was 
stirred for 5 min. Then 400 mg (10.0 mmol) of NaOH (10.0 eq.) was added to this 
solution. The reaction mixture was stirred for 24 h at room temperature. Resulting 
solution was neutralized by 10% HCl. Obtained mixture was extracted with 3x30 ml 
ethyl acetate. The combined organic phase was washed with brine solution (2x25 ml) 
and dried over MgSO4. After the removal of the solvent under vacuum, the crude 
product was purified by column chromatography on silica gel (1:10 EtOAc/Hexanes) to 
give 155.0 mg of (E)-1-(2-hydroxy-5-chlorophenyl)-3-(3-((E)-3-methylstyryl) 
phenyl)prop-2-en-1-one as yellow solid with 41% yield. Rf = 0.69 (ethyl 
acetate/hexanes, 1:6); 1H NMR (400 MHz, CDCl3) δ = 12.76 (s, 1H), 7.95 (d, J = 15.4 
Hz, 1H), 7.88 (d, J = 2.5 Hz, 1H), 7.74 (s, 1H), 7.63–7.52 (m, 3H), 7.48–7.40 (m, 2H), 
7.39–7.33 (m, 2H), 7.31–7.25 (m, 1H), 7.16–7.08 (m, 3H), 6.99 (d, J = 8.9 Hz, 1H), 
2.40 (s, 3H); 13C NMR (100 MHz, CDCl3) δ = 193.01, 162.40, 146.72, 138.66, 138.64, 
137.09, 136.52, 134.98, 130.40, 129.70, 129.29, 129.20, 129.13, 128.97, 128.12, 
127.65, 127.61, 127.25, 124.20, 123.83, 120.88, 120.57, 119.84, 21.79. 
 
3.1.5.8. (E)-1-(2-hydroxy-5-chlorophenyl)-3-(3-((E)-3-fluorostyryl) 
phenyl)prop-2-en-1-one (148) 
 
 A mixture of 226.0 mg (1.0 mmol) of (E)-3-(3-fluorostyryl)benzaldehyde and 
170.0 mg (1.0 mmol) of 5-chloro-2-hydroxyacetophenone in anhydrous ethanol was 
stirred for 5 min. Then 400 mg (10.0 mmol) of NaOH (10.0 eq.) was added to this 
solution. The reaction mixture was stirred for 24 h at room temperature. Resulting 
solution was neutralized by 10% HCl. Obtained mixture was extracted with 3x30 ml 
ethyl acetate. The combined organic phase was washed with brine solution (2x25 ml) 
and dried over MgSO4. After the removal of the solvent under vacuum, the crude 
product was purified by column chromatography on silica gel (1:10 EtOAc/Hexanes) to 
give 86.2 mg of (E)-1-(2-hydroxy-5-chlorophenyl)-3-(3-((E)-3-fluorostyryl) 
phenyl)prop-2-en-1-one as yellow solid with 23% yield. Rf = 0.58 (ethyl 
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acetate/hexanes, 1:6); 1H NMR (400 MHz, CDCl3) δ = 12.72 (s, 1H), 7.96 (d, J = 15.4 
Hz, 1H), 7.90 (d, J = 2.5 Hz, 1H), 7.77 (d, J = 1.6 Hz, 1H), 7.63–7.56 (m, 3H), 7.49–
7.42 (m, 2H), 7.38–7.24 (m, 3H), 7.14 (s, 2H), 7.00 (d, J = 8.9 Hz, 2H); 13C NMR (100 
MHz, CDCl3) δ = 193.05, 164.79, 162.46, 162.34, 146.55, 139.64, 139.57, 138.19, 
136.60, 135.19, 130.59, 130.51, 129.83, 129.44, 129.27, 129.20, 129.17, 128.50, 
127.43, 123.92, 123.00, 122.97, 120.95, 120.64, 120.20, 115.27, 115.06, 113.40, 
113.19. 
 
3.1.5.9. (E)-1-(2-hydroxy-6-methoxyphenyl)-3-(3-((E)-4-methoxystyryl) 
phenyl)prop-2-en-1-one (149) 
 
 A mixture of 238.0 mg (1.0 mmol) of (E)-3-(4-methoxylstyryl)benzaldehyde 
and 166.0 mg (1.0 mmol) of 2-hydroxy-6-methoxyacetophenone in anhydrous ethanol 
was stirred for 5 min. Then 400 mg (10.0 mmol) of NaOH (10.0 eq.) was added to this 
solution. The reaction mixture was stirred for 24 h at room temperature. Resulting 
solution was neutralized by 10% HCl. Obtained mixture was extracted with 3x30 ml 
ethyl acetate. The combined organic phase was washed with brine solution (2x25 ml) 
and dried over MgSO4. After the removal of the solvent under vacuum, the crude 
product was purified by column chromatography on silica gel (1:10 EtOAc/Hexanes) to 
give 211.0 mg of (E)-1-(2-hydroxy-6-methoxyphenyl)-3-(3-((E)-4-methoxylstyryl) 
phenyl)prop-2-en-1-one as yellow solid with 55% yield. Rf = 0.24 (ethyl 
acetate/hexanes, 1:6; 1H NMR (400 MHz, CDCl3) δ = 13.15 (s, 1H), 7.92–7.78 (m, 2H), 
7.67 (s, 1H), 7.57–7.44 (m, 4H), 7.42–7.33 (m, 2H), 7.11 (d, J = 16.3 Hz, 1H), 6.99 (d, 
J = 16.3 Hz, 1H), 6.95–6.88 (m, 2H), 6.64 (dd, J = 8.4, 0.8 Hz, 1H), 6.44 (dd, J = 8.3, 
0.7 Hz, 1H), 3.96 (s, 3H), 3.84 (s, 3H); 13C NMR (100 MHz, CDCl3) δ = 194.76, 
165.18, 161.31, 159.85, 143.21, 138.68, 136.28, 136.02, 130.10, 129.50, 128.23, 
128.18, 128.13, 127.13, 127.08, 126.08, 114.52, 112.33, 111.29, 101.90, 56.33, 55.66. 
 
3.1.5.10. (E)-1-(2-hydroxy-6-methoxyphenyl)-3-(3-((E)-4-methylstyryl) 
phenyl)prop-2-en-1-one (150) 
 
 A mixture of 222.0 mg (1.0 mmol) of (E)-3-(4-methylstyryl)benzaldehyde and 
166.0 mg (1.0 mmol) of 2-hydroxy-6-methoxyacetophenone in anhydrous ethanol was 
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stirred for 5 min. Then 400 mg (10.0 mmol) of NaOH (10.0 eq.) was added to this 
solution. The reaction mixture was stirred for 24 h at room temperature. Resulting 
solution was neutralized by 10% HCl. Obtained mixture was extracted with 3x30 ml 
ethyl acetate. The combined organic phase was washed with brine solution (2x25 ml) 
and dried over MgSO4. After the removal of the solvent under vacuum, the crude 
product was purified by column chromatography on silica gel (1:10 EtOAc/Hexanes) to 
give 163.0 mg of (E)-1-(2-hydroxy-6-methoxyphenyl)-3-(3-((E)-4-methylstyryl) 
phenyl)prop-2-en-1-one as yellow solid with 44% yield. Rf = 0.35 (ethyl 
acetate/hexanes, 1:6); 1H NMR (400 MHz, CDCl3) δ = 13.12 (s, 1H), 7.93–7.80 (m, 
2H), 7.70 (s, 1H), 7.58–7.48 (m, 2H), 7.46–7.34 (m, 4H), 7.22–7.03 (m, 4H), 6.64 (dd, J 
= 8.4, 0.8 Hz, 1H), 6.45 (d, J = 8.3 Hz, 1H), 3.97 (s, 3H), 2.38 (s, 3H); 13C NMR (100 
MHz, CDCl3) δ = 194.66, 165.17, 161.25, 143.07, 138.45, 138.12, 136.22, 135.95, 
134.45, 129.80, 129.73, 129.43, 128.30, 128.06, 127.23, 127.15, 127.11, 126.81, 
112.23, 111.20, 101.84, 56.22, 21.56. 
 
3.1.5.11. (E)-1-(2-hydroxy-6-methoxyphenyl)-3-(3-((E)-3-methylstyryl) 
phenyl)prop-2-en-1-one (151) 
 
 A mixture of 222.0 mg (1.0 mmol) of (E)-3-(3-methylstyryl)benzaldehyde and 
166.0 mg (1.0 mmol) of 2-hydroxy-6-methoxyacetophenone in anhydrous ethanol was 
stirred for 5 min. Then 400 mg (10.0 mmol) of NaOH (10.0 eq.) was added to this 
solution. The reaction mixture was stirred for 24 h at room temperature. Resulting 
solution was neutralized by 10% HCl. Obtained mixture was extracted with 3x30 ml 
ethyl acetate. The combined organic phase was washed with brine solution (2x25 ml) 
and dried over MgSO4. After the removal of the solvent under vacuum, the crude 
product was purified by column chromatography on silica gel (1:10 EtOAc/Hexanes) to 
give 286.0 mg of (E)-1-(2-hydroxy-6-methoxyphenyl)-3-(3-((E)-3-methylstyryl) 
phenyl)prop-2-en-1-one as yellow solid with 78% yield. Rf = 0.38 (ethyl 
acetate/hexanes, 1:6); 1H NMR (400 MHz, CDCl3) δ 13.16 (d, J = 3.6 Hz, 1H), 7.93–
7.79 (m, 2H), 7.70 (s, 1H), 7.59–7.50 (m, 2H), 7.45–7.32 (m, 4H), 7.31–7.23 (m, 1H), 
7.16–7.08 (m, 3H), 6.64 (dd, J = 8.4, 0.9 Hz, 1H), 6.45 (d, J = 8.2 Hz, 1H), 3.97 (s, 3H), 
2.40 (s, 3H); 13C NMR (100 MHz, CDCl3) δ = 194.74, 165.21, 161.34, 143.06, 138.61, 
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138.49, 137.28, 136.25, 136.11, 130.12, 129.52, 129.09, 128.96, 128.42, 128.25, 
128.03, 127.63, 127.44, 127.24, 124.14, 112.38, 111.33, 101.93, 56.33, 21.75. 
 
3.1.5.12. (E)-1-(2-hydroxy-6-methoxyphenyl)-3-(3-((E)-3-fluorostyryl) 
phenyl)prop-2-en-1-one (152) 
 
 A mixture of 226.0 mg (1.0 mmol) of (E)-3-(3-fluorostyryl)benzaldehyde and 
166.0 mg (1.0 mmol) of 2-hydroxy-6-methoxyacetophenone in anhydrous ethanol was 
stirred for 5 min. Then 400 mg (10.0 mmol) of NaOH (10.0 eq.) was added to this 
solution. The reaction mixture was stirred for 24 h at room temperature. Resulting 
solution was neutralized by 10% HCl. Obtained mixture was extracted with 3x30 ml 
ethyl acetate. The combined organic phase was washed with brine solution (2x25 ml) 
and dried over MgSO4. After the removal of the solvent under vacuum, the crude 
product was purified by column chromatography on silica gel (1:10 EtOAc/Hexanes) to 
give 288.0 mg of (E)-1-(2-hydroxy-6-methoxyphenyl)-3-(3-((E)-3-fluorostyryl) 
phenyl)prop-2-en-1-one as yellow solid with 77% yield. Rf = 0.31 (ethyl 
acetate/hexanes, 1:6); 1H NMR (400 MHz, CDCl3) δ = 13.13 (s, 1H), 7.89 (d, J = 15.6 
Hz, 1H), 7.82 (d, J = 15.6 Hz, 1H), 7.69 (s, 1H), 7.58–7.51 (m, 2H), 7.45–7.20 (m, 5H), 
7.11 (s, 2H), 7.02–6.94 (m, 1H), 6.63 (dd, J = 8.4, 1.0 Hz, 1H), 6.44 (dd, J = 8.3, 0.7 
Hz, 1H), 3.97 (s, 3H); 13C NMR (100 MHz, CDCl3) δ = 194.72, 165.22, 164.77, 162.32, 
161.34, 142.87, 139.76, 139.69, 137.91, 136.32, 136.22, 130.56, 130.47, 129.62, 
129.61, 128.79, 128.77, 128.53, 128.41, 127.87, 127.42, 122.94, 122.91, 115.13, 
114.92, 113.32, 113.10, 112.37, 111.36, 101.94, 56.35. 
 
3.1.5.13. (E)-1-(2-hydroxy-4-methoxyphenyl)-3-(3-((E)-4-
methoxystyryl)phenyl)prop-2-en-1-one (153) 
 
 A mixture of 238.0 mg (1.0 mmol) of (E)-3-(4-methoxystyryl)benzaldehyde and 
166.0 mg (1.0 mmol) of 2-hydroxy-4-methoxyacetophenone  in anhydrous ethanol was 
stirred for 5 min. Then 400 mg (10.0 mmol) of NaOH (10.0 eq.) was added to this 
solution. The reaction mixture was stirred for 24 h at room temperature. Resulting 
solution was neutralized by 10% HCl. Obtained mixture was extracted with 3x30 ml 
ethyl acetate. The combined organic phase was washed with brine solution (2x25 ml) 
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and dried over MgSO4. After the removal of the solvent under vacuum, the crude 
product was purified by column chromatography on silica gel (1:10 EtOAc/Hexanes) to 
give 78.5 mg of (E)-1-(2-hydroxy-4-methoxyphenyl)-3-(3-((E)-4-methoxystyryl) 
phenyl)prop-2-en-1-one as yellow solid with 20% yield. Rf = 0.40 (ethyl 
acetate/hexanes, 1:6); 1H NMR (400 MHz, CDCl3) δ = 13.45 (s, 1H), 7.93–7.83 (m, 
2H), 7.72 (s, 1H), 7.60 (d, J = 15.5 Hz, 1H), 7.57–7.45 (m, 4H), 7.40 (dd, J = 7.7, 7.7 
Hz, 1H), 7.12 (d, J = 16.3 Hz, 1H), 7.04–6.88 (m, 3H), 6.54–6.46 (m, 2H), 3.86 (s, 3H), 
3.84 (s, 3H); 13C NMR (100 MHz, CDCl3) δ = 192.14, 167.09, 166.60, 159.91, 144.71, 
138.84, 135.51, 131.62, 130.09, 129.69, 129.59, 128.61, 128.24, 128.22, 127.50, 
126.75, 125.96, 120.85, 114.55, 114.46, 108.13, 101.42, 55.95, 55.68. 
 
3.1.5.14. (E)-1-(2-hydroxy-4-methoxyphenyl)-3-(3-((E)-4-methylstyryl) 
phenyl)prop-2-en-1-one (154) 
 
 A mixture of 222.0 mg (1.0 mmol) of (E)-3-(4-methylstyryl)benzaldehyde and 
166.0 mg (1.0 mmol) of 2-hydroxy-4-methoxyacetophenone in anhydrous ethanol was 
stirred for 5 min. Then 400 mg (10.0 mmol) of NaOH (10.0 eq.) was added to this 
solution. The reaction mixture was stirred for 24 h at room temperature. Resulting 
solution was neutralized by 10% HCl. Obtained mixture was extracted with 3x30 ml 
ethyl acetate. The combined organic phase was washed with brine solution (2x25 ml) 
and dried over MgSO4. After the removal of the solvent under vacuum, the crude 
product was purified by column chromatography on silica gel (1:10 EtOAc/Hexanes) to 
give 167.5 mg of (E)-1-(2-hydroxy-4-methoxyphenyl)-3-(3-((E)-4-methylstyryl) 
phenyl)prop-2-en-1-one as yellow solid with 45% yield. Rf = 0.39 (ethyl 
acetate/hexanes, 1:6); product could not be purified from 2-hydroxy-4-
methoxyacetophenone completely. However it was used in synthesis of product 169. 
 
3.1.5.15. (E)-1-(2-hydroxy-4-methoxyphenyl)-3-(3-((E)-3-methylstyryl) 
phenyl)prop-2-en-1-one (155) 
 
 A mixture of 222.0 mg (1.0 mmol) of (E)-3-(3-methylstyryl)benzaldehyde and 
166.0 mg (1.0 mmol) of 2-hydroxy-4-methoxyacetophenone in anhydrous ethanol was 
stirred for 5 min. Then 400 mg (10.0 mmol) of NaOH (10.0 eq.) was added to this 
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solution. The reaction mixture was stirred for 24 h at room temperature. Resulting 
solution was neutralized by 10% HCl. Obtained mixture was extracted with 3x30 ml 
ethyl acetate. The combined organic phase was washed with brine solution (2x25 ml) 
and dried over MgSO4. After the removal of the solvent under vacuum, the crude 
product was purified by column chromatography on silica gel (1:10 EtOAc/Hexanes) to 
give 163.0 mg of (E)-1-(2-hydroxy-4-methoxyphenyl)-3-(3-((E)-3-methylstyryl) 
phenyl)prop-2-en-1-one as yellow solid with 56% yield. Rf = 0.40 (ethyl 
acetate/hexanes, 1:6); product could not be purified from 2-hydroxy-4-
methoxyacetophenone completely. However it was used in synthesis of product 170. 
 
3.1.5.16. (E)-1-(2-hydroxy-4-methoxyphenyl)-3-(3-((E)-3-fluorostyryl) 
phenyl)prop-2-en-1-one (156) 
 
 A mixture of 226.0 mg (1.0 mmol) of (E)-3-(3-fluorostyryl)benzaldehyde and 
166.0 mg (1.0 mmol) of 2-hydroxy-4-methoxyacetophenone in anhydrous ethanol was 
stirred for 5 min. Then 400 mg (10.0 mmol) of NaOH (10.0 eq.) was added to this 
solution. The reaction mixture was stirred for 24 h at room temperature. Resulting 
solution was neutralized by 10% HCl. Obtained mixture was extracted with 3x30 ml 
ethyl acetate. The combined organic phase was washed with brine solution (2x25 ml) 
and dried over MgSO4. After the removal of the solvent under vacuum, the crude 
product was purified by column chromatography on silica gel (1:10 EtOAc/Hexanes) to 
give 101.0 mg of (E)-1-(2-hydroxy-4-methoxyphenyl)-3-(3-((E)-3-fluorostyryl) 
phenyl)prop-2-en-1-one as yellow solid with 27% yield. Rf = 0.40 (ethyl 
acetate/hexanes, 1:6); product could not be purified from 2-hydroxy-4-
methoxyacetophenone completely. However it was used in synthesis of product 171. 
 
3.1.5.17. (E)-1-(2-hydroxy-4,6-dimethoxyphenyl)-3-(3-((E)-4-
methoxystyryl)phenyl)prop-2-en-1-one (139) 
 
 A mixture of 200.0 mg (0.8 mmol) of (E)-3-(4-methoxylstyryl)benzaldehyde 
and 170.0 mg (0.8 mmol) of 2-hydroxy-4,6-dimethoxyacetophenone in anhydrous 
ethanol was stirred for 5 min. Then 280 mg (7.0 mmol) of NaOH (9.0 eq.) was added to 
this solution. The reaction mixture was stirred for 18 h at room temperature. Resulting 
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solution was neutralized by 10% HCl. Obtained mixture was extracted with 3x30 ml 
ethyl acetate. The combined organic phase was washed with brine solution (2x25 ml) 
and dried over MgSO4. After the removal of the solvent under vacuum, the crude 
product was purified by column chromatography on silica gel (1:10 EtOAc/Hexanes) to 
give 153.0 mg of (E)-1-(2-hydroxy-4,6-dimethoxyphenyl)-3-(3-((E)-4-
methoxylstyryl)phenyl)prop-2-en-1-one as yellow solid with 44% yield. Rf = 0.20 
(ethyl acetate/hexanes, 1:6); 1H NMR (400 MHz, CDCl3) δ = 7.95–7.88 (m, 1H), 7.79 
(d, J = 15.6 Hz, 1H), 7.65 (s, 1H), 7.54–7.44 (m, 4H), 7.37 (dd, J = 7.7 Hz, 1H), 7.10 (d, 
J = 16.3 Hz, 1H), 6.98 (d, J = 16.3 Hz, 1H), 6.94–6.88 (m, 2H), 6.11 (d, J = 2.4 Hz, 
1H), 5.95 (dd, J = 9.9, 2.4 Hz, 1H), 3.92 (s, 3H), 3.83 (s, 6H); 13C NMR (100 MHz, 
CDCl3) δ = 192.88, 168.73, 166.55, 162.81, 159.81, 142.56, 138.60, 136.24, 130.12, 
129.42, 129.37, 128.15, 128.05, 127.97, 127.00, 126.97, 126.14, 114.49, 106.65, 94.12, 
91.58, 56.19, 55.89, 55.64. 
 
3.1.6. Synthesis of Stilbene Fused Flavanone Derivatives  
(126,140,157-171) 
 
3.1.6.1. (E)-6-methoxy-2-(3-(4-methoxystyryl)phenyl)chroman-4-one 
(126) 
 
 185.0 mg (0.6 mmol) of 2-(3-bromophenyl)-6-methoxychroman-4-one and 80.0 
mg (0.6 mmol) of 4-methoxystyrene were placed in two necked flask with magnetic bar 
under nitrogen atmosphere. To this solution 15.0 mg (0.07 mmol) of palladium (II) 
acetate and 2.0 ml of triethanolamine were added. The mixture was stirred and heated at 
100 oC for 10 h. Then solution was cooled to room temperature and extracted with 
diethyl ether (3x30 ml). The combined organic phase was washed with water (40 ml) 
and brine (2x40 ml) and dried overMgSO4. After removal of the solvent under vacuum, 
purification of the crude product was performed by column chromatography on silica 
gel (1:8 EtOAc/Hexanes) to furnish 93.0 mg of (E)-6-methoxy-2-(3-(4-
methoxystyryl)phenylchroman-4-one as white powder with 43% yield. Rf = 0.24 (ethyl 
acetate/hexanes, 1:6); 1H NMR (400 MHz, CDCl3) δ = 7.60 (s, 1H), 7.53–7.44 (m, 3H), 
7.44–7.31 (m, 3H), 7.18–7.07 (m, 2H), 7.06–6.96 (m, 2H), 6.95–6.87 (m, 2H), 5.45 (dd, 
J = 13.4, 2.9 Hz, 1H), 3.84 (s, 3H), 3.83 (s, 3H), 3.10 (dd, J=17.0, 13.5 Hz, 1H), 2.90 
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(dd, J = 17.0, 2.9 Hz, 1H); 13C NMR (100 MHz, CDCl3) δ = 192.32, 159.79, 156.57, 
154.57, 139.59, 138.64, 130.16, 129.44, 129.35, 128.13, 126.82, 126.29, 125.68, 
125.14, 124.26, 121.10, 119.77, 114.49, 107.71, 80.04, 56.12, 55.63, 44.96. 
 
3.1.6.2. (E)-6-methoxy-2-(3-(4-methylstyryl)phenyl)chroman-4-one 
(157) 
 
 89 mg (0.240 mmol) of (E)-1-(2-hydroxy-5-methoxyphenyl)-3-(3-((E)-4-
methylstyryl)phenyl)prop-2-en-1-one and 196.8 mg (2.4 mmol) of sodium acetate were 
heated in refluxing ethanol (8 ml) for 48 hours under nitrogen atmosphere. The mixture 
then allowed to cool to room temperature and poured into cold water (20 ml) and then 
extracted with ethyl acetate (2x25 ml). The combined organic phase was washed with 
brine and dried over MgSO4. After concentrated under vacuum, crude product was 
purified by column chromatography on silica gel (12.5-25 % ethyl acetate in hexanes) 
to afford 65.4 mg of (E)-6-methoxy-2-(3-(4-methylstyryl)phenylchroman-4-one as 
white solid with 73.4% yield. Rf = 0.33 (ethyl acetate/hexanes, 1:6); 1H NMR (400 
MHz, CDCl3) δ = 7.62 (s, 1H), 7.52 (d, J = 7.6 Hz, 1H), 7.47–7.32 (m, 5H), 7.22–7.05 
(m, 5H), 7.03 (d, J = 9.0 Hz, 1H), 5.45 (dd, J = 13.4, 2.4 Hz, 1H), 3.83 (s, 3H), 3.10 (dd, 
J = 16.9, 13.5 Hz, 1H), 2.91 (dd, J = 17.0, 2.8 Hz, 1H), 2.37 (s, 3H); 13C NMR (100 
MHz, CDCl3) δ = 192.35, 156.58, 154.58, 139.61, 138.50, 138.12, 134.58, 129.76, 
129.47, 127.40, 126.98, 126.83, 125.73, 125.35, 124.42, 121.09, 119.79, 107.69, 80.04, 
56.13, 44.97, 21.60. 
 
3.1.6.3. (E)-6-methoxy-2-(3-(3-methylstyryl)phenyl)chroman-4-one 
(158) 
 
 125 mg (0.337 mmol) of (E)-1-(2-hydroxy-5-methoxyphenyl)-3-(3-((E)-3-
methylstyryl)phenyl)prop-2-en-1-one and 277 mg (3.37 mmol) of sodium acetate were 
heated in refluxing ethanol (8 ml) for 48 hours under nitrogen atmosphere. The mixture 
then allowed to cool to room temperature and poured into cold water (20 ml) and then 
extracted with ethyl acetate (2x25 ml). The combined organic phase was washed with 
brine and dried over MgSO4. After concentrated under vacuum, crude product was 
purified by column chromatography on silica gel (12.5-25 % ethyl acetate in hexanes) 
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to afford 90 mg of (E)-6-methoxy-2-(3-(3-methylstyryl)phenylchroman-4-one as white 
solid with 72.0% yield. Rf = 0.33 (ethyl acetate/hexanes, 1:6); 1H NMR (400 MHz, 
CDCl3) δ = 7.64 (s, 1H), 7.53 (dt, J = 7.6, 1.3 Hz, 1H), 7.46–7.32 (m, 5H), 7.30–7.24 
(m, 1H), 7.17–7.08 (m, 4H), 7.03 (d, J = 9.0 Hz, 1H), 5.45 (dd, J = 13.4, 2.9 Hz, 1H), 
3.83 (s, 3H), 3.10 (dd, J = 16.9, 13.5 Hz, 1H), 2.97–2.84 (m, 1H), 2.40 (s, 3H); 13C 
NMR (100 MHz, CDCl3) δ = 192.23, 156.49, 154.52, 139.60, 138.52, 138.33, 137.24, 
129.87, 129.42, 128.97, 128.89, 128.13, 127.56, 126.98, 125.64, 125.43, 124.47, 
124.07, 121.05, 119.72, 107.64, 79.94, 56.05, 44.89, 21.72. 
 
3.1.6.4. (E)-6-methoxy-2-(3-(3-fluorostyryl)phenyl)chroman-4-one 
(159) 
 
 75 mg (0.240 mmol) of (E)-1-(2-hydroxy-5-methoxyphenyl)-3-(3-((E)-3-
fluorostyryl)phenyl)prop-2-en-1-one and 196.8 mg (2.40 mmol) of sodium acetate were 
heated in refluxing ethanol (8 ml) for 48 hours nitrogen atmosphere. The mixture then 
allowed to cool to room temperature and poured into cold water (20 ml) and then 
extracted with ethyl acetate (2x25 ml). The combined organic phase was washed with 
brine and dried over MgSO4. After concentrated under vacuum, crude product was 
purified by column chromatography on silica gel (12.5-25 % ethyl acetate in hexanes) 
to afford 57.3 mg of (E)-6-methoxy-2-(3-(3-fluorostyryl)phenylchroman-4-one as white 
solid with 76.4% yield. Rf = 0.30 (ethyl acetate/hexanes, 1:6); 1H NMR (400 MHz, 
CDCl3) δ = 7.62 (s, 1H), 7.52 (dt, J = 7.6, 1.5 Hz, 1H), 7.42 (dd, J = 7.6, 7.6 Hz, 1H), 
7.39–7.35 (m, 2H), 7.35–7.24 (m, 2H), 7.24–7.19 (m, 1H), 7.16–7.09 (m, 3H), 7.01 (d, 
J = 9.0 Hz, 1H), 6.96 (dddd, J = 9.6, 8.6, 2.6, 1.3 Hz, 1H), 5.45 (dd, J = 13.4, 2.9 Hz, 
1H), 3.82 (s, 3H), 3.08 (dd, J = 17.0, 13.4 Hz, 1H), 2.90 (dd, J = 17.0, 2.9 Hz, 1H). 
13C NMR (100 MHz, CDCl3) δ = 192.20, 164.69, 162.25, 156.49, 154.59, 139.75, 
139.68, 137.79, 130.50, 130.41, 129.71, 129.54, 128.60, 128.57, 127.19, 125.92, 
125.71, 124.64, 122.87, 122.84, 121.08, 119.74, 115.03, 114.82, 113.26, 113.04, 
107.69, 79.90, 56.10, 44.94. 
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3.1.6.5. (E)-6-chloro-2-(3-(4-methoxystyryl)phenyl)chroman-4-one 
(160) 
 
 A solution of 39 mg (0.100 mmol) of (E)-1-(2-hydroxy-5-chlorophenyl)-3-(3-
((E)-4-methoxylstyryl)phenyl)prop-2-en-1-one and 13.46 mg (1.20 mmol) of potassium 
tert-butoxide were heated in refluxing ethanol (8 ml) for 48 hours nitrogen atmosphere. 
The mixture then allowed to cool to room temperature and poured into cold water (20 
ml) and then extracted with ethyl acetate (2x25 ml). The combined organic phase was 
washed with brine and dried over MgSO4. After concentrated under vacuum, crude 
product was purified by column chromatography on silica gel (1:14 EtOAc/Hexanes) to 
afford 24 mg of (E)-6-chloro-2-(3-(4-methoxystyryl)phenylchroman-4-one as white 
solid with 62% yield. Rf = 0.35 (ethyl acetate/hexanes, 1:6); 1H NMR (400 MHz, 
CDCl3) δ = 7.90 (d, J = 2.6 Hz, 1H), 7.58 (s, 1H), 7.55–7.38 (m, 5H), 7.32 (d, J = 7.6 
Hz, 1H), 7.18–6.95 (m, 3H), 6.95–6.88 (m, 2H), 5.48 (dd, J = 13.3, 2.9 Hz, 1H), 3.84 (s, 
3H), 3.11 (dd, J = 17.0, 13.3 Hz, 1H), 2.93 (dd, J = 17.0, 3.0 Hz, 1H); 13C NMR (100 
MHz, CDCl3) δ = 191.15, 160.29, 159.85, 139.01, 138.76, 136.38, 130.10, 129.55, 
129.52, 128.17, 127.56, 127.05, 126.75, 126.16, 125.12, 124.26, 122.04, 120.24, 
114.52, 80.19, 55.67, 44.69. 
 
3.1.6.6. (E)-6-chloro-2-(3-(4-methylstyryl)phenyl)chroman-4-one (161) 
 
 96.5 mg (0.256 mmol) of (E)-1-(2-hydroxy-5-chlorophenyl)-3-(3-((E)-4-
methylstyryl)phenyl)prop-2-en-1-one and 210.0 mg (2.56 mmol) of sodium acetate 
were heated in refluxing ethanol (8 ml) for 48 hours nitrogen atmosphere. The mixture 
then allowed to cool to room temperature and poured into cold water (20 ml) and then 
extracted with ethyl acetate (2x25 ml). The combined organic phase was washed with 
brine and dried over MgSO4. After concentrated under vacuum, crude product was 
purified by column chromatography on silica gel (12.5-25 % ethyl acetate in hexanes) 
to afford 15 mg of (E)-6-chloro-2-(3-(4-methylstyryl)phenylchroman-4-one as white 
solid with 26.4% yield. Rf = 0.50 (ethyl acetate/hexanes, 1:6); 1H NMR (400 MHz, 
CDCl3) δ = 7.91 (d, J = 2.5 Hz, 1H), 7.60 (s, 1H), 7.54 (d, J = 7.7 Hz, 1H), 7.50–7.39 
(m, 4H), 7.33 (d, J = 7.6 Hz, 1H), 7.22–7.01 (m, 5H), 5.49 (dd, J = 13.3, 2.5 Hz, 1H), 
3.11 (dd, J = 17.0, 13.3 Hz, 1H), 2.93 (dd, J = 17.0, 2.9 Hz, 1H), 2.37 (s, 3H); 13C NMR 
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(100 MHz, CDCl3) δ = 191.13, 160.29, 139.03, 138.63, 138.23, 136.38, 134.52, 129.93, 
129.80, 129.57, 127.58, 127.28, 127.19, 126.85, 126.76, 125.32, 124.42, 122.05, 
120.24, 80.17, 44.70, 21.62. 
 
3.1.6.7. (E)-6-chloro-2-(3-(3-methylstyryl)phenyl)chroman-4-one (162) 
 
 93 mg (0.248 mmol) of (E)-1-(2-hydroxy-5-chlorophenyl)-3-(3-((E)-3-
methylstyryl)phenyl)prop-2-en-1-one and 203 mg (2.48 mmol) of sodium acetate were 
heated in refluxing ethanol (8 ml) for 48 hours under nitrogen atmosphere. The mixture 
then allowed to cool to room temperature and poured into cold water (20 ml) and then 
extracted with ethyl acetate (2x25 ml). The combined organic phase was washed with 
brine and dried over MgSO4. After concentrated under vacuum, crude product was 
purified by column chromatography on silica gel (12.5-25 % ethyl acetate in hexanes) 
to afford 71 mg of (E)-6-chloro-2-(3-(3-methylstyryl)phenylchroman-4-one as white 
solid with 76.3% yield. Rf = 0.50 (ethyl acetate/hexanes, 1:6); 1H NMR (400 MHz, 
CDCl3) δ = 7.81 (d, J = 2.3Hz, 1H), 7.50 (s, 1H), 7.44 (d, J = 7.7 Hz, 1H), 7.39–7.29 
(m, 2H), 7.28–7.12 (m, 4H), 7.05–6.91 (m, 4H), 5.37 (d, J = 13.2 Hz, 1H), 3.07–2.92 
(m, 1H), 2.82 (d, J = 17.0 Hz, 1H), 2.29 (s, 3H); 13C NMR (100 MHz, cdcl3) δ = 191.03, 
160.23, 139.04, 138.59, 138.48, 137.21, 136.33, 130.06, 129.54, 129.07, 128.94, 
128.03, 127.60, 127.53, 127.21, 126.72, 125.42, 124.48, 124.10, 122.01, 120.20, 80.10, 
44.63, 21.75. 
 
3.1.6.8. (E)-6-chloro-2-(3-(3-fluorostyryl)phenyl)chroman-4-one (163) 
 
 77 mg (0.203 mmol) of (E)-1-(2-hydroxy-5-chlorophenyl)-3-(3-((E)-3-
fluorostyryl)phenyl)prop-2-en-1-one and 166 mg (2.03 mmol) of sodium acetate were 
heated in refluxing ethanol (8 ml) for 48 hours under nitrogen atmosphere. The mixture 
then allowed to cool to room temperature and poured into cold water (20 ml) and then 
extracted with ethyl acetate (2x25 ml). The combined organic phase was washed with 
brine and dried over MgSO4. After concentrated under vacuum, crude product was 
purified by column chromatography on silica gel (12.5-25 % ethyl acetate in hexanes) 
to afford 58 mg of (E)-6-chloro-2-(3-(3-fluorostyryl)phenylchroman-4-one as white 
solid with 77.3% yield. Rf = 0.45 (ethyl acetate/hexanes, 1:6); 1H NMR (400 MHz, 
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CDCl3) δ = 7.90 (s, 1H), 7.64–7.40 (m, 4H), 7.40–7.19 (m, 4H), 7.12 (s, 2H), 7.05 (dd, 
J = 8.8, 1.9 Hz, 1H), 6.98 (dd, J = 8.4, 8.4 Hz, 1H), 5.49 (d, J = 13.2 Hz, 1H), 3.18–3.03 
(m, 1H), 2.93 (d, J = 16.9 Hz, 1H); 13C NMR (100 MHz, CDCl3) δ = 207.10, 190.82, 
164.58, 162.14, 160.08, 139.58, 139.50, 139.06, 137.78, 136.23, 136.22, 130.41, 
130.32, 130.31, 129.48, 128.62, 128.60, 127.46, 127.26, 126.61, 126.60, 126.56, 
125.76, 124.53, 124.51, 122.77, 122.75, 121.90, 120.07, 114.98, 114.76, 113.16, 
113.15, 112.94, 79.89, 44.51. 
 
3.1.6.9. (E)-5-methoxy-2-(3-(4-methoxystyryl)phenyl)chroman-4-one 
(164) 
 
 75 mg (0.194 mmol) of (E)-1-(2-hydroxy-6-methoxyphenyl)-3-(3-((E)-4-
methoxystyryl)phenyl)prop-2-en-1-one and 159 mg (1.94 mmol) of sodium acetate 
were heated in refluxing ethanol (8 ml) for 48 hours under nitrogen atmosphere. The 
mixture then allowed to cool to room temperature and poured into cold water (20 ml) 
and then extracted with ethyl acetate (2x25 ml). The combined organic phase was 
washed with brine and dried over MgSO4. After concentrated under vacuum, crude 
product was purified by column chromatography on silica gel (12.5-25 % ethyl acetate 
in hexanes) to afford 59.1 mg of (E)-5-methoxy-2-(3-(4-methoxystyryl)phenylchroman-
4-one as white solid with 78.8% yield. Rf = 0.25 (ethyl acetate/hexanes, 1:2); 1H NMR 
(400 MHz, CDCl3) δ = 7.57 (s, 1H), 7.50–7.35 (m, 5H), 7.30 (d, J = 7.7 Hz, 1H), 7.09 
(d, J = 16.3 Hz, 1H), 6.98 (d, J = 16.3 Hz, 1H), 6.92–6.86 (m, 2H), 6.68 (dd, J = 8.3, 0.6 
Hz, 1H), 6.54 (d, J = 8.2 Hz, 1H), 5.42 (dd, J = 13.2, 2.8 Hz, 1H), 3.92 (s, 3H), 3.81 (s, 
3H), 3.08 (dd, J = 16.4, 13.3 Hz, 1H), 2.86 (dd, J = 16.4, 2.9 Hz, 1H); 13C NMR (100 
MHz, CDCl3) δ = 190.95, 163.44, 161.05, 159.72, 139.42, 138.55, 136.35, 130.14, 
129.38, 129.26, 128.10, 126.75, 126.27, 125.09, 124.18, 114.45, 111.65, 110.51, 
104.38, 79.24, 56.51, 55.60, 46.30. 
 
3.1.6.10. (E)-5-methoxy-2-(3-(4-methylstyryl)phenyl)chroman-4-one 
(165) 
 
 85 mg (0.23 mmol) of (E)-1-(2-hydroxy-6-methoxyphenyl)-3-(3-((E)-4-
methylstyryl)phenyl)prop-2-en-1-one and 189 mg (2.3 mmol) of sodium acetate were 
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heated in refluxing ethanol (8 ml) for 48 hours under nitrogen atmosphere. The mixture 
then allowed to cool to room temperature and poured into cold water (20 ml) and then 
extracted with ethyl acetate (2x25 ml). The combined organic phase was washed with 
brine and dried over MgSO4. After concentrated under vacuum, crude product was 
purified by column chromatography on silica gel (12.5-25 % ethyl acetate in hexanes) 
to afford 54 mg of (E)-5-methoxy-2-(3-(4-methylstyryl)phenylchroman-4-one as white 
solid with 63.5% yield. Rf = 0.35 (ethyl acetate/hexanes, 1:2); 1H NMR (400 MHz, 
CDCl3) δ = 7.60 (s, 1H), 7.53–7.49 (m, 1H), 7.46–7.38 (m, 4H), 7.34 (d, J = 7.7 Hz, 
1H), 7.20–7.15 (m, 2H), 7.11 (d, J = 7.1 Hz, 2H), 6.70 (dd, J = 8.4, 0.9 Hz, 1H), 6.56 
(dd, J = 8.4, 0.7 Hz, 1H), 5.45 (dd, J = 13.2, 2.9 Hz, 1H), 3.94 (s, 3H), 3.10 (dd, J = 
16.4, 13.2 Hz, 1H), 2.89 (dd, J = 16.5, 2.9 Hz, 1H), 2.37 (s, 3H); 13C NMR (100 MHz, 
CDCl3) δ = 190.93, 163.44, 161.06, 139.45, 138.41, 138.04, 136.36, 134.56, 129.72, 
129.67, 129.39, 127.39, 126.89, 126.79, 125.29, 124.33, 111.65, 110.51, 104.39, 79.22, 
56.52, 46.31, 21.57. 
 
3.1.6.11. (E)-5-methoxy-2-(3-(3-methylstyryl)phenyl)chroman-4-one 
(166) 
 
 99 mg (0.267 mmol) of (E)-1-(2-hydroxy-6-methoxyphenyl)-3-(3-((E)-3-
methylstyryl)phenyl)prop-2-en-1-one and 219 mg (2.67 mmol) of sodium acetate were 
heated in refluxing ethanol (8 ml) for 48 hours under nitrogen atmosphere. The mixture 
then allowed to cool to room temperature and poured into cold water (20 ml) and then 
extracted with ethyl acetate (2x25 ml). The combined organic phase was washed with 
brine and dried over MgSO4. After concentrated under vacuum, crude product was 
purified by column chromatography on silica gel (12.5-25 % ethyl acetate in hexanes) 
to afford 60 mg of (E)-5-methoxy-2-(3-(3-methylstyryl)phenylchroman-4-one as white 
solid with 60.6% yield. Rf = 0.35 (ethyl acetate/hexanes, 1:2); 1H NMR (400 MHz, 
CDCl3) δ = 7.61 (s, 1H), 7.52 (dt, J = 7.7, 1.4 Hz, 1H), 7.45–7.38 (m, 2H), 7.37–7.31 
(m, 3H), 7.30–7.23 (m, 1H), 7.13 (s, 2H), 7.10 (d, J = 7.4 Hz, 1H), 6.70 (dd, J = 8.3, 0.9 
Hz, 1H), 6.56 (dd, J = 8.4, 0.8 Hz, 1H), 5.45 (dd, J = 13.2, 2.9 Hz, 1H), 3.93 (s, 3H), 
3.10 (dd, J = 16.5, 13.2 Hz, 1H), 2.89 (dd, J = 16.5, 2.9 Hz, 1H), 2.39 (s, 3H); 13C NMR 
(100 MHz, CDCl3) δ = 190.85, 163.40, 161.03, 139.46, 138.50, 138.28, 137.25, 136.33, 
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129.81, 129.38, 128.93, 128.87, 128.15, 127.54, 126.92, 125.39, 124.40, 124.05, 
111.63, 110.48, 104.37, 79.17, 56.48, 46.27, 21.71. 
 
3.1.6.12. (E)-5-methoxy-2-(3-(3-fluorostyryl)phenyl)chroman-4-one 
(167) 
 
 110 mg (0.294 mmol) of (E)-1-(2-hydroxy-6-methoxyphenyl)-3-(3-((E)-3-
fluorostyryl)phenyl)prop-2-en-1-one and 241 mg (2.94 mmol) of sodium acetate were 
heated in refluxing ethanol (8 ml) for 48 hours under nitrogen atmosphere. The mixture 
then allowed to cool to room temperature and poured into cold water (20 ml) and then 
extracted with ethyl acetate (2x25 ml). The combined organic phase was washed with 
brine and dried over MgSO4. After concentrated under vacuum, crude product was 
purified by column chromatography on silica gel (12.5-25 % ethyl acetate in hexanes) 
to afford 62 mg of (E)-5-methoxy-2-(3-(3-fluorostyryl)phenylchroman-4-one as white 
solid with 56.4% yield. Rf = 0.30 (ethyl acetate/hexanes, 1:2); 1H NMR (400 MHz, 
CDCl3) δ = 7.59 (s, 1H), 7.49 (dt, J = 7.6, 1.4 Hz, 1H), 7.43–7.23 (m, 5H), 7.23–7.17 
(m, 1H), 7.11–7.07 (m, 2H), 6.97–6.90 (m, 1H), 6.67 (dd, J = 8.3, 0.8 Hz, 1H), 6.54 (d, 
J = 8.4 Hz, 1H), 5.43 (dd, J = 13.2, 2.9 Hz, 1H), 3.92 (s, 3H), 3.07 (dd, J = 16.4, 13.2 
Hz, 1H), 2.86 (dd, J = 16.4, 3.0 Hz, 1H); 13C NMR (100 MHz, CDCl3) δ = 190.73, 
164.65, 163.34, 162.20, 161.04, 139.74, 139.67, 139.60, 137.70, 136.36, 130.45, 
130.36, 129.71, 129.46, 128.50, 128.48, 127.09, 125.84, 124.56, 124.54, 122.82, 
122.79, 114.95, 114.74, 113.22, 112.99, 111.63, 110.45, 104.43, 104.42, 79.09, 79.07, 
56.50, 56.46, 46.27. 
 
3.1.6.13. (E)-7-methoxy-2-(3-(4-methoxystyryl)phenyl)chroman-4-one 
(168) 
 
 78.5 mg (0.203 mmol) of (E)-1-(2-hydroxy-4-methoxyphenyl)-3-(3-((E)-4-
methoxystyryl)phenyl)prop-2-en-1-one and 166 mg (2.03 mmol) of sodium acetate 
were heated in refluxing ethanol (8 ml) for 48 hours under nitrogen atmosphere. The 
mixture then allowed to cool to room temperature and poured into cold water (20 ml) 
and then extracted with ethyl acetate (2x25 ml). The combined organic phase was 
washed with brine and dried over MgSO4. After concentrated under vacuum, crude 
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product was purified by column chromatography on silica gel (12.5-25 % ethyl acetate 
in hexanes) to afford 53.3 mg of (E)-7-methoxy-2-(3-(4-methoxystyryl)phenylchroman-
4-one as white solid with 67.9% yield. Rf = 0.16 (ethyl acetate/hexanes, 1:6); 1H NMR 
(400 MHz, CDCl3) δ = 7.89 (dd, J = 8.2, 3.8 Hz, 1H), 7.60 (s, 1H), 7.53–7.44 (m, 3H), 
7.41 (dd, J = 7.6, 7.6 Hz, 1H), 7.33 (d, J = 7.7 Hz, 1H), 7.11 (d, J = 16.3 Hz, 1H), 7.00 
(d, J = 16.3 Hz, 1H), 6.94–6.87 (m, 2H), 6.63 (dd, J = 8.8, 2.4 Hz, 1H), 6.53 (d, J = 2.4 
Hz, 1H), 5.47 (dd, J = 13.3, 2.9 Hz, 1H), 3.84 (s, 3H), 3.83 (s, 3H), 3.06 (dd, J = 16.9, 
13.3 Hz, 1H), 2.85 (dd, J = 16.9, 2.9 Hz, 1H); 13C NMR (100 MHz, CDCl3) δ = 190.80, 
166.47, 163.80, 159.77, 139.53, 138.62, 130.12, 129.43, 129.33, 129.06, 128.12, 
126.81, 126.24, 125.13, 124.25, 115.13, 114.47, 110.57, 101.25, 101.22, 80.31, 80.29, 
55.96, 55.92, 55.62, 55.58, 44.68. 
 
3.1.6.14. (E)-7-methoxy-2-(3-(4-methylstyryl)phenyl)chroman-4-one 
(169) 
 
 82 mg (0.223 mmol) of (E)-1-(2-hydroxy-4-methoxyphenyl)-3-(3-((E)-4-
methylstyryl)phenyl)prop-2-en-1-one and 183 mg (2.23 mmol) of sodium acetate were 
heated in refluxing ethanol (8 ml) for 48 hours under nitrogen atmosphere. The mixture 
then allowed to cool to room temperature and poured into cold water (20 ml) and then 
extracted with ethyl acetate (2x25 ml). The combined organic phase was washed with 
brine and dried over MgSO4. After concentrated under vacuum, crude product was 
purified by column chromatography on silica gel (12.5-25 % ethyl acetate in hexanes) 
to afford 26.5 mg of (E)-7-methoxy-2-(3-(4-methylstyryl)phenylchroman-4-one as 
white solid with 32.3% yield. Rf = 0.68 (ethyl acetate/hexanes, 1:2); 1H NMR (400 
MHz, CDCl3) δ = 7.90 (d, J = 8.8 Hz, 1H), 7.62 (s, 1H), 7.53 (d, J = 7.7 Hz, 1H), 7.46–
7.38 (m, 3H), 7.35 (d, J = 7.7 Hz, 1H), 7.22–7.15 (m, 2H), 7.12 (d, J = 7.1 Hz, 2H), 
6.64 (dd, J = 8.8, 2.4 Hz, 1H), 6.54 (d, J = 2.4 Hz, 1H), 5.49 (dd, J = 13.3, 2.9 Hz, 1H), 
3.85 (s, 3H), 3.07 (dd, J = 16.9, 13.3 Hz, 1H), 2.86 (dd, J = 16.9, 3.0 Hz, 1H), 2.37 (s, 
3H); 13C NMR (100 MHz, CDCl3) δ = 190.84, 166.52, 163.84, 139.58, 138.53, 138.13, 
134.58, 129.77, 129.48, 129.10, 127.39, 127.00, 126.83, 125.36, 124.43, 115.16, 
110.65, 110.63, 101.28, 101.26, 101.25, 80.33, 80.32, 56.00, 55.97, 44.72, 21.61, 21.59. 
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3.1.6.15. (E)-7-methoxy-2-(3-(3-methylstyryl)phenyl)chroman-4-one 
(170) 
 
 75 mg (0.202 mmol) of (E)-1-(2-hydroxy-4-methoxyphenyl)-3-(3-((E)-3-
methylstyryl)phenyl)prop-2-en-1-one and 165.6 mg (2.02 mmol) of sodium acetate 
were heated in refluxing ethanol (8 ml) for 48 hours under nitrogen atmosphere. The 
mixture then allowed to cool to room temperature and poured into cold water (20 ml) 
and then extracted with ethyl acetate (2x25 ml). The combined organic phase was 
washed with brine and dried over MgSO4. After concentrated under vacuum, crude 
product was purified by column chromatography on silica gel (12.5-25 % ethyl acetate 
in hexanes) to afford 54.8 mg of (E)-7-methoxy-2-(3-(3-methylstyryl)phenylchroman-4-
one as white solid with 73% yield. Rf = 0.70 (ethyl acetate/hexanes, 1:2); 1H NMR (400 
MHz, CDCl3) δ = 7.93–7.86 (m, 1H), 7.63 (s, 1H), 7.56–7.50 (m, 1H), 7.43 (dd, J = 9.5, 
5.7 Hz, 1H), 7.38–7.31 (m, 3H), 7.26 (dd, J = 9.4, 5.7 Hz, 1H), 7.13 (s, 2H), 7.10 (d, J = 
7.4 Hz, 1H), 6.64 (dd, J = 8.8, 2.4 Hz, 1H), 6.54 (d, J = 2.4 Hz, 1H), 5.48 (dd, J = 13.3, 
2.9 Hz, 1H), 3.84 (s, 3H), 3.07 (dd, J = 16.9, 13.3 Hz, 1H), 2.86 (dd, J = 16.9, 3.0 Hz, 
1H), 2.39 (s, 3H); 13C NMR (100 MHz, CDCl3) δ = 190.81, 166.51, 163.81, 139.59, 
138.57, 138.41, 137.28, 129.94, 129.48, 129.09, 129.01, 128.93, 128.16, 127.59, 
127.05, 125.48, 124.51, 124.10, 115.14, 110.63, 101.26, 80.28, 55.97, 44.70, 21.75. 
 
3.1.6.16. (E)-7-methoxy-2-(3-(3-fluoroystyryl)phenyl)chroman-4-one 
(171) 
 
 58 mg (0.155 mmol) of (E)-1-(2-hydroxy-4-methoxyphenyl)-3-(3-((E)-3-
fluorostyryl)phenyl)prop-2-en-1-one and 127 mg (1.55 mmol) of sodium acetate were 
heated in refluxing ethanol (8 ml) for 48 hours under nitrogen atmosphere. The mixture 
then allowed to cool to room temperature and poured into cold water (20 ml) and then 
extracted with ethyl acetate (2x25 ml). The combined organic phase was washed with 
brine and dried over MgSO4. After concentrated under vacuum, crude product was 
purified by column chromatography on silica gel (12.5-25 % ethyl acetate in hexanes) 
to afford 28.6 mg of (E)-7-methoxy-2-(3-(3-fluorostyryl)phenylchroman-4-one as white 
solid with 49.3% yield. Rf = 0.70 (ethyl acetate/hexanes, 1:2); 1H NMR (400 MHz, 
CDCl3) δ = 7.81 (d, J = 8.8 Hz, 1H), 7.55 (s, 1H), 7.45 (d, J = 7.6 Hz, 1H), 7.35 (dd, J = 
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7.6, 7.6 Hz, 1H), 7.32–7.12 (m, 4H), 7.04 (d, J = 2.3 Hz, 2H), 6.93–6.85 (m, 1H), 6.55 
(dd, J = 8.8, 2.4 Hz, 1H), 6.45 (d, J = 2.4 Hz, 1H), 5.41 (dd, J = 13.3, 2.9 Hz, 1H), 3.76 
(s, 3H), 2.98 (dd, J = 16.9, 13.3 Hz, 1H), 2.78 (dd, J = 16.9, 3.0, 1H); 13C NMR (100 
MHz, CDCl3) δ = 190.73, 166.56, 164.73, 163.79, 162.29, 139.79, 139.75, 139.71, 
137.85, 130.53, 130.44, 129.74, 129.60, 129.14, 128.66, 128.63, 127.25, 125.96, 
124.68, 124.67, 122.89, 122.86, 115.17, 115.07, 114.86, 113.29, 113.07, 110.69, 
110.66, 101.31, 101.29, 101.27, 80.24, 80.23, 56.03, 55.98, 44.74. 
 
3.1.6.17. (E)-5,7-dimethoxy-2-(3-(4-methoxystyryl)phenyl)chroman-4-
one (140) 
 
 102 mg (0.245 mmol) of (E)-1-(2-hydroxy-4-methoxyphenyl)-3-(3-((E)-3-
fluorostyryl)phenyl)prop-2-en-1-one and 201 mg (2.45 mmol) of sodium acetate were 
heated in refluxing ethanol (8 ml) for 48 hours under nitrogen atmosphere. The mixture 
then allowed to cool to room temperature and poured into cold water (20 ml) and then 
extracted with ethyl acetate (2x25 ml). The combined organic phase was washed with 
brine and dried over MgSO4. After concentrated under vacuum, crude product was 
purified by column chromatography on silica gel (12.5-25 % ethyl acetate in hexanes) 
to afford 66.3 mg of (E)-5,7-methoxy-2-(3-(4-methoxystyryl)phenylchroman-4-one as 
white solid with 65% yield. Rf = 0.13 (ethyl acetate/hexanes, 1:2); 1H NMR (400 MHz, 
CDCl3) δ = 7.57 (s, 1H), 7.52–7.43 (m, 3H), 7.39 (dd, J = 7.6 Hz, 1H), 7.31 (d, J = 7.7 
Hz, 1H), 7.10 (d, J = 16.3 Hz, 1H), 6.99 (d, J = 16.3 Hz, 1H), 6.94–6.86 (m, 2H), 6.19 
(d, J = 2.3 Hz, 1H), 6.10 (d, J = 2.3 Hz, 1H), 5.42 (dd, J = 13.2, 2.9 Hz, 1H), 3.90 (s, 
3H), 3.82 (s, 6H), 3.05 (dd, J = 16.5, 13.3 Hz, 1H), 2.82 (dd, J = 16.6, 2.9 Hz, 1H); 13C 
NMR (100 MHz, CDCl3) δ = 189.48, 166.27, 165.26, 162.57, 159.73, 139.47, 138.54, 
130.14, 129.37, 129.25, 128.09, 126.74, 126.28, 125.10, 124.20, 114.45, 106.27, 93.86, 
93.49, 79.50, 56.45, 55.91, 55.60, 45.93. 
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3.2. Measuring Cell Viability Test 
 
3.2.1. General Methods 
 
 PC3 cells were maintained in Dulbecco‘s modified Eagle‘s medium (DMEM) 
containing 5% fetal bovine serum (FBS), 100 µg/ml streptomycin/100IU/ml penicillin, 
MCF7 cell line was maintained in Roswell Park Memorial Institude-1640 (RPMI-1640) 
containing 15% FBS (BIO-IND), 100 µg/ml streptomycin/100IU/ml penicillin 
incubated at 37 ºC in the dark with 5% CO2 humidified incubator and passaged when 
they reached 80-85% confluency. Cells used in experiments were maintained from 10-
20th passages. 
 
3.2.2. MTT Tests for Compounds 
 
 To investigate the cytotoxic activity of the compounds, 95 µl of cell suspension 
was inoculated into 96-well microculture plates at 1x104 cells density per well in culture 
media containing FBS, penicillin/streptomycin. Compounds were dissolved in 
dimethylsulfoxide (DMSO) (Sigma Chemical Co.), filter sterilized, diluted at the 
appropriate concentrations with the culture medium. In all well, 1% DMSO 
concentration was fixed. Dilutions of compounds were freshly prepared before each 
experiment. After 24h cultivation for cell attachment, compounds were added at final 
concentration 50, 25, 1, 0.5, 0.1, 0.05, and 0.01 µM for triplicate assay. Cells were 
treated with the compounds for 48 hours and cytotoxic effects were determined by 
tetrazolium (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide) (Sigma 
Chemical Co.) based colorimetric assay. This method depends on the cleavage of 
tetrazolium salt to purple formazan crystals by mitochondrial enzymes of metabolically 
active cells (Ciapetti, et al. 1993). Briefly; 4 hours before end of incubation period, 
medium of the cells was removed and wells were washed by pre-warmed phosphate-
buffered saline (PBS) to remove any trace of compounds and to prevent colour 
interference while optical density determination. MTT stock solution (5mg/ml) was 
diluted at 1:10 ratio into complete culture media, 100 µl of MTT dilution was added 
into each well and incubated. After 3.5 hours plates were centrifuged at 1800 rpm for 10 
minute at room temperatures to avoid accidental removal of formazan crystals. Crystals 
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were dissolved with 100µl DMSO. The absorbance was determined at 540nm. Results 
were represented as percentage viability and calculated by the following formula 
(Equation 3.1). 
 
% viability=[(ODs-ODb/ODc-ODb)x100]                               (3.1) 
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CHAPTER 4  
 
CONCLUSION 
 
 Stilbenes, flavanones and chalcones are valuable, biologically active 
compounds. In this thesis, stilbene fused chalcones and stilbene fused flavanones were 
designed as potential biologically active compounds. 
 Syntheses of target compounds were accomplished by two alternative routes. 
Because of the problematic Heck reactions of halogenated flavanones at the first route, 
stilbene formations were done in first step at second route. Then formed stilbenes were 
subjected to aldol reactions in basic ethanol solution. Finally cyclization reactions were 
carried out with sodium acetate in ethanol. Synthesis of two small libraries of stilbene 
fused chalcones and stilbene fused flavanones were successfully prepared. 
 Selected examples from these libraries were evaluated their cytotoxic activities 
over PC3 and MCF-7 cancer cell lines. One of the stilbene fused flavanones‘ 
cytotoxicity compared with the cytotoxicities of corresponding simple flavanone and 
stilbene structure. These preliminary cytotoxicity tests show that selected stilbene fused 
flavanone shows higher cytotoxicity than simple flavanone and stilbene structure over 
PC3 cell lines. Addition to that, stilbene fused chalcones are much more toxic than 
stilbene fused flavanones over both cancer cell lines. Finally cytotoxicities of stilbene 
fused chalcones can be altered by changing the substituents coming from styrene and 
acetophenones started with. Stilbene fused chalcones, having methyl substituent on 
styryl part, has found the most active compound so far. To tell more about the structure 
activity relationship of libraries more cytotoxicity test is on the way. 
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